LCD/NCD Portal
Automated World Health
L29168
ERYTHROPOIESIS STIMULATING AGENTS
01/01/2013
Indications and Limitations of Coverage and/or Medical Necessity
This LCD will outline the indications and limitations for Erythropoesis stimulating agents (ESAs) for Renal and Non-renal indications.
Indications:
Epoetin alfa (Procrit® and Epogen®)
Epoetin alfa is covered for the following FDA approved labeled, indications:
• Anemia due to Chronic Kidney Disease.
o Epoetin alfa is indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and not on dialysis to decrease the need for red blood cell (RBC) transfusion.
• Anemia due to Zidovudine in HIV-infected patients.
o Epoetin alfa is indicated for the treatment of anemia due to zidovudine administered at ≤ 4200 mg/week HIV-infected patients with endogenous serum erythropoietin levels of ≤ 500 mUnits/mL.
• Reduction of allogeneic red blood cell transfusions in patients undergoing elective, noncardiac, nonvascular surgery.
o Epoetin alfa is indicated to reduce the need for allogeneic RBC transfusions among patients with perioperative hemoglobin >10 to ≤13 g/dL who are at high risk for perioperative blood loss from elective, noncardiac, nonvascular surgery.
o Epoetin alfa is not indicated for patients who are willing to donate autologous blood pre-operatively.
• Anemia due to chemotherapy in patients with cancer.
o Coverage for this indication is outlined in the NCD issued on 7/30/07 for ESAs in cancer and related neoplastic conditions and is summarized under the “limitations” section of this LCD.
In addition to the FDA labeled indications, epoetin alfa is covered for the following off-label indications:
• For the treatment of anemia associated with myelodysplastic syndrome (MDS).
o Patients usually present with variable clinical features depending on the MDS classification and the degree of disordered hematopoiesis with anemia.
o Common complaints or symptoms are fatigue, pallor, infection and bleeding or bruising. Diagnosis is usually confirmed by bone marrow aspiration and/or biopsy.
o For the purposes of this LCD, Chronic Myelomonocytic Leukemia (CMML) will be considered a form of MDS and as such the anemia associated with it may be eligible for coverage if the indications and limitations outlined in this LCD for MDS are met.
o Providers must use the ICD-9 codes listed in the LCD for MDS to code for CMML.
o If the physician cannot classify the patient with one of the MDS diagnosis codes, then the patient does not meet the criteria for CMML and coverage will not have been met.
• For the treatment of anemia associated with the management of hepatitis C.
o The use of epoetin alfa has been shown to be effective in treatment of anemia in patients with hepatitis C virus infection who are being treated with the combination of ribavarin and interferon alfa or ribavarin and peginterferon alfa
• For the treatment of chronic anemia associated Rheumatoid Arthritis (RA).
o The patient must have been previously diagnosed with RA using the American College of Rheumatology criteria. Patients are usually on antimetabolite (e.g., Methotrexate) which causes the anemia.
Darbepoetin alfa (Aranesp®)
Darbepoetin alfa is covered for the following FDA approved, labeled, indications:
• Anemia due to chronic kidney disease (CKD).
o Aranesp is indicated for the treatment of anemia due to CKD, including patients on dialysis and patients not on dialysis.
• Anemia due to chemotherapy in patients with cancer.
o Coverage for this indication is outlined in the NCD issued on 7/30/07 for ESAs in cancer and related neoplastic conditions and is summarized in the “limitations” section of this LCD.
In addition to the FDA labeled indications, Darbepoetin alfa is covered for the following off-label indications:
• For the treatment of anemia associated with myelodysplastic syndrome (MDS).
o Patients usually present with variable clinical features depending on the MDS classification and the degree of disordered hematopoiesis with anemia.
o Common complaints or symptoms are fatigue, pallor, infection and bleeding or bruising.
o Diagnosis is usually confirmed by bone marrow aspiration and/or biopsy.
o For the purposes of this LCD, Chronic Myelomonocytic Leukemia (CMML) will be considered a form of MDS and as such the anemia associated with it may be eligible for coverage if the indications and limitations outlined in this LCD for MDS are met.
o Providers must use the ICD-9 codes listed in the LCD for MDS to code for CMML.
o If the physician cannot classify the patient with one of the MDS diagnosis codes, then the patient does not meet the criteria for CMML and coverage will not have been met.
• Peginesatide (OMONTYS®)
Peginesatide is covered for the following FDA approved labeled, indications:
• Anemia due to chronic kidney disease (CKD). Peginesatide is indicated for the treatment of anemia due to CKD in adult patients on dialysis.
Limitations
• ESAs are not indicated for use:
o In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy.
o In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure.
o In patients scheduled for surgery who are willing to donate autologous blood. (applies to epotein alfa products only-Epogen and Procrit).
o In patients undergoing cardiac or vascular surgery. (applies to epoetin alfa products only-Epogen and Procrit).
o As a substitute for RBC transfusions in patients who require immediate correction of anemia.
o
• Prior to initiating ESA therapy, other causes of anemia should be ruled out and managed if present.
o Evaluate the iron status in all patients before and during treatment and maintain iron repletion.
o Correct or exclude other causes of anemia.
Vitamin deficiency.
Metabolic.
Chronic inflammatory conditions.
Bleeding.
o Other causes could also be
Iron deficiency.
Underlying infectious.
Inflammatory or malignant processes.
Occult blood loss.
Underlying hematologic diseases.
Hemolysis.
Aluminum intoxication.
Osteitis fibrosa cystica.
Pure Red blood Cell Aplasia.
• Epoetin alfa, Darbepoetin alfa, and Peginesatide are contraindicated in patients with uncontrolled hypertension.
• Epoetin alfa is also contraindicated in patients with known hypersensitivity to mammalian cell-derived products and to Albumin (Human).
• Darbepoetin alfa is contraindicated in patients with known hypersensitivity to the active substance or any of the excipients of darbepoetin alfa.
• Peginesatide is not indicated and is not recommended for use:
o In patients with CKD not on dialysis.
o In patients receiving treatment for cancer and whose anemia is not due to CKD.
• For patients in the ESRD program: Generally, ESRD patients with symptomatic anemia considered for initiation of EPO/Aranesp therapy should have a hematocrit less than 30 or hemoglobin less than 10.
• ESRD patients who have been receiving EPO/Aranesp therapy should have a hematocrit between 30 and 36.Refer to Pub 100-02, Chapter 11, Section 90 and Pub 100-02, Chapter 15, Section 50.5.2 for further discussion.
The FDA has issued a black box warning for ESAs. The Black Box Warning reads as follows:
• Chronic Kidney Disease:
o In controlled trials, patients experienced greater risk for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target a hemoglobin level of greater than 11 g/dL.
o No trial has identified a hemoglobin target, ESA dose, or dosing strategy that does not increase these risks.
o Use the lowest epoetin alfa, darbepoetin alfa or peginesatide dose sufficient to reduce the need for red blood cell (RBC) transfusion.
• Cancer:
o ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in clinical studies of patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers.
o Because of these risks, prescribers and hospitals must enroll in and comply with the ESA APPRISE Oncology Program to prescribe and/or dispense epoetin alfa to patients with cancer.
o To decrease these risks, as well as the risk of serious cardiovascular and thromboembolic reactions, use the lowest dose needed to avoid RBC transfusions.
o Use ESAs only for anemia from myelosuppressive chemotherapy.
o ESAs are not indicated for patients receiving myelosuppressive chemotherapy when the anticipated outcome is cure.
o Discontinue following the completion of a chemotherapy course.
• Perisurgery
o Due to increased risk of deep vein thrombosis (DVT), DVT prophylaxis is recommended.
• Renal failure:
o Patients experienced greater risk for death and serious cardiovascular events when administered erythropoiesis-stimulating agents (ESAs) to target higher versus lower hemoglobin levels (13.5vs 11.3g/dL; 14 vs. 10g/dL) in two clinical studies.
o Individualize dosing to achieve and maintain hemoglobin levels within the range of 10 to 12 g/dL.
CMS issued a National Coverage Decision for ESAs for non-ESRD use.
The following limitations have been imposed by the NCD and are effective for services on or after 7/30/2007:
• ESA treatment is NOT reasonable and necessary for the following clinical conditions:
o Any anemia in cancer or cancer treatment patients due to folate deficiency, B-12 deficiency, iron deficiency, hemolysis, bleeding or bone marrow fibrosis.
o The anemia associated with the treatment of acute and chronic myelogenous leukemias (CML, AML), or erythroid cancers.
o The anemia of cancer not related to cancer treatment.
o Anemia associated only with radiotherapy.
o Prophylactic use to prevent chemotherapy-induced anemia.
o Prophylactic use to reduce tumor hypoxia.
o Patients with erythropoietin-type resistance due to neutralizing antibodies.
o Anemia due to cancer treatment if patients have uncontrolled hypertension.
CMS has also determined that ESA treatment for the anemia secondary to myelosuppressive anticancer chemotherapy in:
• Solid tumors.
• Multiple myeloma.
• Lymphoma.
• Lymphocytic leukemia.
And only reasonable and necessary under the following specified conditions:
• The hemoglobin level immediately prior to initiation or maintenance of ESA treatment is <10 g/L (or the Hematocrit is <30%).
• The starting dose for ESA treatment is the recommended FDA label starting dose, no more than 150 U/kg/three times weekly for epoetin and 2.25 mcg/kg/weekly for Darbepoetin alfa. Equivalent doses may be given over other approved time periods.
• Maintenance of ESA therapy is the starting dose if the hemoglobin level remains below 10 g/dL (or Hematocrit is <30%) 4 weeks after initiation of therapy and the rise in hemoglobin is ≥ 1g/dL (or Hematocrit is ≥ 3%).
• For patients whose hemoglobin rise <1 g/dl (Hematocrit rise <3%) compared to pretreatment baseline over 4 weeks of treatment and whose hemoglobin level remains <10 g/dL after 4 weeks of treatment (or the hematocrit <30%), the recommended FDA label starting dose may be increased once by 25%. Continued use of the drug is not reasonable or necessary if the hemoglobin rises <1 g/dL (Hematocrit is <3%) compared to pretreatment baseline by 8 weeks of treatment.
• Continued administration of the drug is not reasonable and necessary if there is a rapid rise in hemoglobin > 1g/dl (Hematocrit is <30%). Continuation and reinstitution of ESA therapy must include a dose reduction of 25% from the previously administered dose.
• ESA treatment duration for each course of chemotherapy includes the 8 weeks following the final dose of myelosuppressive chemotherapy in a chemotherapy regimen.
CPT/HCPCS Codes
J0881 INJECTION, DARBEPOETIN ALFA, 1 MICROGRAM (NON-ESRD USE)
J0882 INJECTION, DARBEPOETIN ALFA, 1 MICROGRAM (FOR ESRD ON DIALYSIS)
J0885 INJECTION, EPOETIN ALFA, (FOR NON-ESRD USE), 1000 UNITS
J0886 INJECTION, EPOETIN ALFA, 1000 UNITS (FOR ESRD ON DIALYSIS)
J0890 INJECTION, PEGINESATIDE, 0.1 MG (FOR ESRD ON DIALYSIS)
ICD-9 Codes that Support Medical Necessity
J0881 List 1
The diagnosis codes listed below require the use of the EC modifier when submitting claims for J0881. In addition, diagnosis codes marked with an * require a dual diagnosis. The dual diagnosis rule is outlined below.
Dual diagnosis rule:
1.) 403.01, 403.11, 403.91, 404.02, 404.03, 404.12, 404.13, 404.92, 404.93, 585.1, 585.2, 585.3, 585.4, 585.5 or 585.9 AND 285.21 must be billed together.
238.71 ESSENTIAL THROMBOCYTHEMIA
238.72 LOW GRADE MYELODYSPLASTIC SYNDROME LESIONS
238.73 HIGH GRADE MYELODYSPLASTIC SYNDROME LESIONS
238.74 MYELODYSPLASTIC SYNDROME WITH 5Q DELETION
238.75 MYELODYSPLASTIC SYNDROME, UNSPECIFIED
238.76 MYELOFIBROSIS WITH MYELOID METAPLASIA
273.3 MACROGLOBULINEMIA
285.21* ANEMIA IN CHRONIC KIDNEY DISEASE
403.01* HYPERTENSIVE CHRONIC KIDNEY DISEASE, MALIGNANT, WITH CHRONIC KIDNEY DISEASE STAGE V OR END STAGE RENAL DISEASE
403.11* HYPERTENSIVE CHRONIC KIDNEY DISEASE, BENIGN, WITH CHRONIC KIDNEY DISEASE STAGE V OR END STAGE RENAL DISEASE
403.91* HYPERTENSIVE CHRONIC KIDNEY DISEASE, UNSPECIFIED, WITH CHRONIC KIDNEY DISEASE STAGE V OR END STAGE RENAL DISEASE
404.02* HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE, MALIGNANT, WITHOUT HEART FAILURE AND WITH CHRONIC KIDNEY DISEASE STAGE V OR END STAGE RENAL DISEASE
404.03* HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE, MALIGNANT, WITH HEART FAILURE AND WITH CHRONIC KIDNEY DISEASE STAGE V OR END STAGE RENAL DISEASE
404.12* HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE, BENIGN, WITHOUT HEART FAILURE AND WITH CHRONIC KIDNEY DISEASE STAGE V OR END STAGE RENAL DISEASE
404.13* HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE, BENIGN, WITH HEART FAILURE AND CHRONIC KIDNEY DISEASE STAGE V OR END STAGE RENAL DISEASE
404.92* HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE, UNSPECIFIED, WITHOUT HEART FAILURE AND WITH CHRONIC KIDNEY DISEASE STAGE V OR END STAGE RENAL DISEASE
404.93* HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE, UNSPECIFIED, WITH HEART FAILURE AND CHRONIC KIDNEY DISEASE STAGE V OR END STAGE RENAL DISEASE
585.1* CHRONIC KIDNEY DISEASE, STAGE I
585.2* CHRONIC KIDNEY DISEASE, STAGE II (MILD)
585.3* CHRONIC KIDNEY DISEASE, STAGE III (MODERATE)
585.4* CHRONIC KIDNEY DISEASE, STAGE IV (SEVERE)
585.5* CHRONIC KIDNEY DISEASE, STAGE V
585.9* CHRONIC KIDNEY DISEASE, UNSPECIFIED
J0881 List 2
The following diagnosis codes require the use of the EA modifier when
submitting claims for J0881. In addition, ALL diagnosis codes listed below require a dual diagnosis. The dual diagnosis rule is outlined below.
Dual Diagnosis Rule
1.) ALL diagnosis codes listed below for J0881 List 2 require a dual diagnosis in addition to the EA modifier. Diagnosis code 285.3 AND one of the malignancy codes listed below MUST be billed together. All codes listed below except for 285.3 are malignancy codes.
140.0 MALIGNANT NEOPLASM OF UPPER LIP VERMILION BORDER
140.1 MALIGNANT NEOPLASM OF LOWER LIP VERMILION BORDER
140.3 MALIGNANT NEOPLASM OF UPPER LIP INNER ASPECT
140.4 MALIGNANT NEOPLASM OF LOWER LIP INNER ASPECT
140.5 MALIGNANT NEOPLASM OF LIP UNSPECIFIED INNER ASPECT
140.6 MALIGNANT NEOPLASM OF COMMISSURE OF LIP
140.8 MALIGNANT NEOPLASM OF OTHER SITES OF LIP
140.9 MALIGNANT NEOPLASM OF LIP UNSPECIFIED VERMILION BORDER
141.0 MALIGNANT NEOPLASM OF BASE OF TONGUE
141.1 MALIGNANT NEOPLASM OF DORSAL SURFACE OF TONGUE
141.2 MALIGNANT NEOPLASM OF TIP AND LATERAL BORDER OF TONGUE
141.3 MALIGNANT NEOPLASM OF VENTRAL SURFACE OF TONGUE
141.4 MALIGNANT NEOPLASM OF ANTERIOR TWO-THIRDS OF TONGUE PART UNSPECIFIED
141.5 MALIGNANT NEOPLASM OF JUNCTIONAL ZONE OF TONGUE
141.6 MALIGNANT NEOPLASM OF LINGUAL TONSIL
141.8 MALIGNANT NEOPLASM OF OTHER SITES OF TONGUE
141.9 MALIGNANT NEOPLASM OF TONGUE UNSPECIFIED
142.0 MALIGNANT NEOPLASM OF PAROTID GLAND
142.1 MALIGNANT NEOPLASM OF SUBMANDIBULAR GLAND
142.2 MALIGNANT NEOPLASM OF SUBLINGUAL GLAND
142.8 MALIGNANT NEOPLASM OF OTHER MAJOR SALIVARY GLANDS
142.9 MALIGNANT NEOPLASM OF SALIVARY GLAND UNSPECIFIED
143.0 MALIGNANT NEOPLASM OF UPPER GUM
143.1 MALIGNANT NEOPLASM OF LOWER GUM
143.8 MALIGNANT NEOPLASM OF OTHER SITES OF GUM
143.9 MALIGNANT NEOPLASM OF GUM UNSPECIFIED
144.0 MALIGNANT NEOPLASM OF ANTERIOR PORTION OF FLOOR OF MOUTH
144.1 MALIGNANT NEOPLASM OF LATERAL PORTION OF FLOOR OF MOUTH
144.8 MALIGNANT NEOPLASM OF OTHER SITES OF FLOOR OF MOUTH
144.9 MALIGNANT NEOPLASM OF FLOOR OF MOUTH PART UNSPECIFIED
145.0 MALIGNANT NEOPLASM OF CHEEK MUCOSA
145.1 MALIGNANT NEOPLASM OF VESTIBULE OF MOUTH
145.2 MALIGNANT NEOPLASM OF HARD PALATE
145.3 MALIGNANT NEOPLASM OF SOFT PALATE
145.4 MALIGNANT NEOPLASM OF UVULA
145.5 MALIGNANT NEOPLASM OF PALATE UNSPECIFIED
145.6 MALIGNANT NEOPLASM OF RETROMOLAR AREA
145.8 MALIGNANT NEOPLASM OF OTHER SPECIFIED PARTS OF MOUTH
145.9 MALIGNANT NEOPLASM OF MOUTH UNSPECIFIED
146.0 MALIGNANT NEOPLASM OF TONSIL
146.1 MALIGNANT NEOPLASM OF TONSILLAR FOSSA
146.2 MALIGNANT NEOPLASM OF TONSILLAR PILLARS (ANTERIOR) (POSTERIOR)
146.3 MALIGNANT NEOPLASM OF VALLECULA EPIGLOTTICA
146.4 MALIGNANT NEOPLASM OF ANTERIOR ASPECT OF EPIGLOTTIS
146.5 MALIGNANT NEOPLASM OF JUNCTIONAL REGION OF OROPHARYNX
146.6 MALIGNANT NEOPLASM OF LATERAL WALL OF OROPHARYNX
146.7 MALIGNANT NEOPLASM OF POSTERIOR WALL OF OROPHARYNX
146.8 MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF OROPHARYNX
146.9 MALIGNANT NEOPLASM OF OROPHARYNX UNSPECIFIED SITE
147.0 MALIGNANT NEOPLASM OF SUPERIOR WALL OF NASOPHARYNX
147.1 MALIGNANT NEOPLASM OF POSTERIOR WALL OF NASOPHARYNX
147.2 MALIGNANT NEOPLASM OF LATERAL WALL OF NASOPHARYNX
147.3 MALIGNANT NEOPLASM OF ANTERIOR WALL OF NASOPHARYNX
147.8 MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF NASOPHARYNX
147.9 MALIGNANT NEOPLASM OF NASOPHARYNX UNSPECIFIED SITE
148.0 MALIGNANT NEOPLASM OF POSTCRICOID REGION OF HYPOPHARYNX
148.1 MALIGNANT NEOPLASM OF PYRIFORM SINUS
148.2 MALIGNANT NEOPLASM OF ARYEPIGLOTTIC FOLD HYPOPHARYNGEAL ASPECT
148.3 MALIGNANT NEOPLASM OF POSTERIOR HYPOPHARYNGEAL WALL
148.8 MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF HYPOPHARYNX
148.9 MALIGNANT NEOPLASM OF HYPOPHARYNX UNSPECIFIED SITE
149.0 MALIGNANT NEOPLASM OF PHARYNX UNSPECIFIED
149.1 MALIGNANT NEOPLASM OF WALDEYER'S RING
149.8 MALIGNANT NEOPLASM OF OTHER SITES WITHIN THE LIP AND ORAL CAVITY
149.9 MALIGNANT NEOPLASM OF ILL-DEFINED SITES WITHIN THE LIP AND ORAL CAVITY
150.0 MALIGNANT NEOPLASM OF CERVICAL ESOPHAGUS
150.1 MALIGNANT NEOPLASM OF THORACIC ESOPHAGUS
150.2 MALIGNANT NEOPLASM OF ABDOMINAL ESOPHAGUS
150.3 MALIGNANT NEOPLASM OF UPPER THIRD OF ESOPHAGUS
150.4 MALIGNANT NEOPLASM OF MIDDLE THIRD OF ESOPHAGUS
150.5 MALIGNANT NEOPLASM OF LOWER THIRD OF ESOPHAGUS
150.8 MALIGNANT NEOPLASM OF OTHER SPECIFIED PART OF ESOPHAGUS
150.9 MALIGNANT NEOPLASM OF ESOPHAGUS UNSPECIFIED SITE
151.0 MALIGNANT NEOPLASM OF CARDIA
151.1 MALIGNANT NEOPLASM OF PYLORUS
151.2 MALIGNANT NEOPLASM OF PYLORIC ANTRUM
151.3 MALIGNANT NEOPLASM OF FUNDUS OF STOMACH
151.4 MALIGNANT NEOPLASM OF BODY OF STOMACH
151.5 MALIGNANT NEOPLASM OF LESSER CURVATURE OF STOMACH UNSPECIFIED
151.6 MALIGNANT NEOPLASM OF GREATER CURVATURE OF STOMACH UNSPECIFIED
151.8 MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF STOMACH
151.9 MALIGNANT NEOPLASM OF STOMACH UNSPECIFIED SITE
152.0 MALIGNANT NEOPLASM OF DUODENUM
152.1 MALIGNANT NEOPLASM OF JEJUNUM
152.2 MALIGNANT NEOPLASM OF ILEUM
152.3 MALIGNANT NEOPLASM OF MECKEL'S DIVERTICULUM
152.8 MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF SMALL INTESTINE
152.9 MALIGNANT NEOPLASM OF SMALL INTESTINE UNSPECIFIED SITE
153.0 MALIGNANT NEOPLASM OF HEPATIC FLEXURE
153.1 MALIGNANT NEOPLASM OF TRANSVERSE COLON
153.2 MALIGNANT NEOPLASM OF DESCENDING COLON
153.3 MALIGNANT NEOPLASM OF SIGMOID COLON
153.4 MALIGNANT NEOPLASM OF CECUM
153.5 MALIGNANT NEOPLASM OF APPENDIX VERMIFORMIS
153.6 MALIGNANT NEOPLASM OF ASCENDING COLON
153.7 MALIGNANT NEOPLASM OF SPLENIC FLEXURE
153.8 MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF LARGE INTESTINE
153.9 MALIGNANT NEOPLASM OF COLON UNSPECIFIED SITE
154.0 MALIGNANT NEOPLASM OF RECTOSIGMOID JUNCTION
154.1 MALIGNANT NEOPLASM OF RECTUM
154.2 MALIGNANT NEOPLASM OF ANAL CANAL
154.3 MALIGNANT NEOPLASM OF ANUS UNSPECIFIED SITE
154.8 MALIGNANT NEOPLASM OF OTHER SITES OF RECTUM RECTOSIGMOID JUNCTION AND ANUS
155.0 MALIGNANT NEOPLASM OF LIVER PRIMARY
155.1 MALIGNANT NEOPLASM OF INTRAHEPATIC BILE DUCTS
155.2 MALIGNANT NEOPLASM OF LIVER NOT SPECIFIED AS PRIMARY OR SECONDARY
156.0 MALIGNANT NEOPLASM OF GALLBLADDER
156.1 MALIGNANT NEOPLASM OF EXTRAHEPATIC BILE DUCTS
156.2 MALIGNANT NEOPLASM OF AMPULLA OF VATER
156.8 MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF GALLBLADDER AND EXTRAHEPATIC BILE DUCTS
156.9 MALIGNANT NEOPLASM OF BILIARY TRACT PART UNSPECIFIED SITE
157.0 MALIGNANT NEOPLASM OF HEAD OF PANCREAS
157.1 MALIGNANT NEOPLASM OF BODY OF PANCREAS
157.2 MALIGNANT NEOPLASM OF TAIL OF PANCREAS
157.3 MALIGNANT NEOPLASM OF PANCREATIC DUCT
157.4 MALIGNANT NEOPLASM OF ISLETS OF LANGERHANS
157.8 MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF PANCREAS
157.9 MALIGNANT NEOPLASM OF PANCREAS PART UNSPECIFIED
158.0 MALIGNANT NEOPLASM OF RETROPERITONEUM
158.8 MALIGNANT NEOPLASM OF SPECIFIED PARTS OF PERITONEUM
158.9 MALIGNANT NEOPLASM OF PERITONEUM UNSPECIFIED
159.0 MALIGNANT NEOPLASM OF INTESTINAL TRACT PART UNSPECIFIED
159.1 MALIGNANT NEOPLASM OF SPLEEN NOT ELSEWHERE CLASSIFIED
159.8 MALIGNANT NEOPLASM OF OTHER SITES OF DIGESTIVE SYSTEM AND INTRA-ABDOMINAL ORGANS
159.9 MALIGNANT NEOPLASM OF ILL-DEFINED SITES WITHIN THE DIGESTIVE ORGANS AND PERITONEUM
160.0 MALIGNANT NEOPLASM OF NASAL CAVITIES
160.1 MALIGNANT NEOPLASM OF AUDITORY TUBE MIDDLE EAR AND MASTOID AIR CELLS
160.2 MALIGNANT NEOPLASM OF MAXILLARY SINUS
160.3 MALIGNANT NEOPLASM OF ETHMOIDAL SINUS
160.4 MALIGNANT NEOPLASM OF FRONTAL SINUS
160.5 MALIGNANT NEOPLASM OF SPHENOIDAL SINUS
160.8 MALIGNANT NEOPLASM OF OTHER ACCESSORY SINUSES
160.9 MALIGNANT NEOPLASM OF ACCESSORY SINUS UNSPECIFIED
161.0 MALIGNANT NEOPLASM OF GLOTTIS
161.1 MALIGNANT NEOPLASM OF SUPRAGLOTTIS
161.2 MALIGNANT NEOPLASM OF SUBGLOTTIS
161.3 MALIGNANT NEOPLASM OF LARYNGEAL CARTILAGES
161.8 MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF LARYNX
161.9 MALIGNANT NEOPLASM OF LARYNX UNSPECIFIED
162.0 MALIGNANT NEOPLASM OF TRACHEA
162.2 MALIGNANT NEOPLASM OF MAIN BRONCHUS
162.3 MALIGNANT NEOPLASM OF UPPER LOBE BRONCHUS OR LUNG
162.4 MALIGNANT NEOPLASM OF MIDDLE LOBE BRONCHUS OR LUNG
162.5 MALIGNANT NEOPLASM OF LOWER LOBE BRONCHUS OR LUNG
162.8 MALIGNANT NEOPLASM OF OTHER PARTS OF BRONCHUS OR LUNG
162.9 MALIGNANT NEOPLASM OF BRONCHUS AND LUNG UNSPECIFIED
163.0 MALIGNANT NEOPLASM OF PARIETAL PLEURA
163.1 MALIGNANT NEOPLASM OF VISCERAL PLEURA
163.8 MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF PLEURA
163.9 MALIGNANT NEOPLASM OF PLEURA UNSPECIFIED
164.0 MALIGNANT NEOPLASM OF THYMUS
164.1 MALIGNANT NEOPLASM OF HEART
164.2 MALIGNANT NEOPLASM OF ANTERIOR MEDIASTINUM
164.3 MALIGNANT NEOPLASM OF POSTERIOR MEDIASTINUM
164.8 MALIGNANT NEOPLASM OF OTHER PARTS OF MEDIASTINUM
164.9 MALIGNANT NEOPLASM OF MEDIASTINUM PART UNSPECIFIED
165.0 MALIGNANT NEOPLASM OF UPPER RESPIRATORY TRACT PART UNSPECIFIED
165.8 MALIGNANT NEOPLASM OF OTHER SITES WITHIN THE RESPIRATORY SYSTEM AND INTRATHORACIC ORGANS
165.9 MALIGNANT NEOPLASM OF ILL-DEFINED SITES WITHIN THE RESPIRATORY SYSTEM
170.0 MALIGNANT NEOPLASM OF BONES OF SKULL AND FACE EXCEPT MANDIBLE
170.1 MALIGNANT NEOPLASM OF MANDIBLE
170.2 MALIGNANT NEOPLASM OF VERTEBRAL COLUMN EXCLUDING SACRUM AND COCCYX
170.3 MALIGNANT NEOPLASM OF RIBS STERNUM AND CLAVICLE
170.4 MALIGNANT NEOPLASM OF SCAPULA AND LONG BONES OF UPPER LIMB
170.5 MALIGNANT NEOPLASM OF SHORT BONES OF UPPER LIMB
170.6 MALIGNANT NEOPLASM OF PELVIC BONES SACRUM AND COCCYX
170.7 MALIGNANT NEOPLASM OF LONG BONES OF LOWER LIMB
170.8 MALIGNANT NEOPLASM OF SHORT BONES OF LOWER LIMB
170.9 MALIGNANT NEOPLASM OF BONE AND ARTICULAR CARTILAGE SITE UNSPECIFIED
171.0 MALIGNANT NEOPLASM OF CONNECTIVE AND OTHER SOFT TISSUE OF HEAD FACE AND NECK
171.2 MALIGNANT NEOPLASM OF CONNECTIVE AND OTHER SOFT TISSUE OF UPPER LIMB INCLUDING SHOULDER
171.3 MALIGNANT NEOPLASM OF CONNECTIVE AND OTHER SOFT TISSUE OF LOWER LIMB INCLUDING HIP
171.4 MALIGNANT NEOPLASM OF CONNECTIVE AND OTHER SOFT TISSUE OF THORAX
171.5 MALIGNANT NEOPLASM OF CONNECTIVE AND OTHER SOFT TISSUE OF ABDOMEN
171.6 MALIGNANT NEOPLASM OF CONNECTIVE AND OTHER SOFT TISSUE OF PELVIS
171.7 MALIGNANT NEOPLASM OF CONNECTIVE AND OTHER SOFT TISSUE OF TRUNK UNSPECIFIED
171.8 MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF CONNECTIVE AND OTHER SOFT TISSUE
171.9 MALIGNANT NEOPLASM OF CONNECTIVE AND OTHER SOFT TISSUE SITE UNSPECIFIED
172.0 MALIGNANT MELANOMA OF SKIN OF LIP
172.1 MALIGNANT MELANOMA OF SKIN OF EYELID INCLUDING CANTHUS
172.2 MALIGNANT MELANOMA OF SKIN OF EAR AND EXTERNAL AUDITORY CANAL
172.3 MALIGNANT MELANOMA OF SKIN OF OTHER AND UNSPECIFIED PARTS OF FACE
172.4 MALIGNANT MELANOMA OF SKIN OF SCALP AND NECK
172.5 MALIGNANT MELANOMA OF SKIN OF TRUNK EXCEPT SCROTUM
172.6 MALIGNANT MELANOMA OF SKIN OF UPPER LIMB INCLUDING SHOULDER
172.7 MALIGNANT MELANOMA OF SKIN OF LOWER LIMB INCLUDING HIP
172.8 MALIGNANT MELANOMA OF OTHER SPECIFIED SITES OF SKIN
172.9 MELANOMA OF SKIN SITE UNSPECIFIED
173.00 UNSPECIFIED MALIGNANT NEOPLASM OF SKIN OF LIP
173.01 BASAL CELL CARCINOMA OF SKIN OF LIP
173.02 SQUAMOUS CELL CARCINOMA OF SKIN OF LIP
173.09 OTHER SPECIFIED MALIGNANT NEOPLASM OF SKIN OF LIP
173.10 UNSPECIFIED MALIGNANT NEOPLASM OF EYELID, INCLUDING CANTHUS
173.11 BASAL CELL CARCINOMA OF EYELID, INCLUDING CANTHUS
173.12 SQUAMOUS CELL CARCINOMA OF EYELID, INCLUDING CANTHUS
173.19 OTHER SPECIFIED MALIGNANT NEOPLASM OF EYELID, INCLUDING CANTHUS
173.20 UNSPECIFIED MALIGNANT NEOPLASM OF SKIN OF EAR AND EXTERNAL AUDITORY CANAL
173.21 BASAL CELL CARCINOMA OF SKIN OF EAR AND EXTERNAL AUDITORY CANAL
173.22 SQUAMOUS CELL CARCINOMA OF SKIN OF EAR AND EXTERNAL AUDITORY CANAL
173.29 OTHER SPECIFIED MALIGNANT NEOPLASM OF SKIN OF EAR AND EXTERNAL AUDITORY CANAL
173.30 UNSPECIFIED MALIGNANT NEOPLASM OF SKIN OF OTHER AND UNSPECIFIED PARTS OF FACE
173.31 BASAL CELL CARCINOMA OF SKIN OF OTHER AND UNSPECIFIED PARTS OF FACE
173.32 SQUAMOUS CELL CARCINOMA OF SKIN OF OTHER AND UNSPECIFIED PARTS OF FACE
173.39 OTHER SPECIFIED MALIGNANT NEOPLASM OF SKIN OF OTHER AND UNSPECIFIED PARTS OF FACE
173.40 UNSPECIFIED MALIGNANT NEOPLASM OF SCALP AND SKIN OF NECK
173.41 BASAL CELL CARCINOMA OF SCALP AND SKIN OF NECK
173.42 SQUAMOUS CELL CARCINOMA OF SCALP AND SKIN OF NECK
173.49 OTHER SPECIFIED MALIGNANT NEOPLASM OF SCALP AND SKIN OF NECK
173.50 UNSPECIFIED MALIGNANT NEOPLASM OF SKIN OF TRUNK, EXCEPT SCROTUM
173.51 BASAL CELL CARCINOMA OF SKIN OF TRUNK, EXCEPT SCROTUM
173.52 SQUAMOUS CELL CARCINOMA OF SKIN OF TRUNK, EXCEPT SCROTUM
173.59 OTHER SPECIFIED MALIGNANT NEOPLASM OF SKIN OF TRUNK, EXCEPT SCROTUM
173.60 UNSPECIFIED MALIGNANT NEOPLASM OF SKIN OF UPPER LIMB, INCLUDING SHOULDER
173.61 BASAL CELL CARCINOMA OF SKIN OF UPPER LIMB, INCLUDING SHOULDER
173.62 SQUAMOUS CELL CARCINOMA OF SKIN OF UPPER LIMB, INCLUDING SHOULDER
173.69 OTHER SPECIFIED MALIGNANT NEOPLASM OF SKIN OF UPPER LIMB, INCLUDING SHOULDER
173.70 UNSPECIFIED MALIGNANT NEOPLASM OF SKIN OF LOWER LIMB, INCLUDING HIP
173.71 BASAL CELL CARCINOMA OF SKIN OF LOWER LIMB, INCLUDING HIP
173.72 SQUAMOUS CELL CARCINOMA OF SKIN OF LOWER LIMB, INCLUDING HIP
173.79 OTHER SPECIFIED MALIGNANT NEOPLASM OF SKIN OF LOWER LIMB, INCLUDING HIP
173.80 UNSPECIFIED MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF SKIN
173.81 BASAL CELL CARCINOMA OF OTHER SPECIFIED SITES OF SKIN
173.82 SQUAMOUS CELL CARCINOMA OF OTHER SPECIFIED SITES OF SKIN
173.89 OTHER SPECIFIED MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF SKIN
173.90 UNSPECIFIED MALIGNANT NEOPLASM OF SKIN, SITE UNSPECIFIED
173.91 BASAL CELL CARCINOMA OF SKIN, SITE UNSPECIFIED
173.92 SQUAMOUS CELL CARCINOMA OF SKIN, SITE UNSPECIFIED
173.99 OTHER SPECIFIED MALIGNANT NEOPLASM OF SKIN, SITE UNSPECIFIED
174.0 MALIGNANT NEOPLASM OF NIPPLE AND AREOLA OF FEMALE BREAST
174.1 MALIGNANT NEOPLASM OF CENTRAL PORTION OF FEMALE BREAST
174.2 MALIGNANT NEOPLASM OF UPPER-INNER QUADRANT OF FEMALE BREAST
174.3 MALIGNANT NEOPLASM OF LOWER-INNER QUADRANT OF FEMALE BREAST
174.4 MALIGNANT NEOPLASM OF UPPER-OUTER QUADRANT OF FEMALE BREAST
174.5 MALIGNANT NEOPLASM OF LOWER-OUTER QUADRANT OF FEMALE BREAST
174.6 MALIGNANT NEOPLASM OF AXILLARY TAIL OF FEMALE BREAST
174.8 MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF FEMALE BREAST
174.9 MALIGNANT NEOPLASM OF BREAST (FEMALE) UNSPECIFIED SITE
175.0 MALIGNANT NEOPLASM OF NIPPLE AND AREOLA OF MALE BREAST
175.9 MALIGNANT NEOPLASM OF OTHER AND UNSPECIFIED SITES OF MALE BREAST
176.0 KAPOSI'S SARCOMA SKIN
176.1 KAPOSI'S SARCOMA SOFT TISSUE
176.2 KAPOSI'S SARCOMA PALATE
176.3 KAPOSI'S SARCOMA GASTROINTESTINAL SITES
176.4 KAPOSI'S SARCOMA LUNG
176.5 KAPOSI'S SARCOMA LYMPH NODES
176.8 KAPOSI'S SARCOMA OTHER SPECIFIED SITES
176.9 KAPOSI'S SARCOMA UNSPECIFIED SITE
179 MALIGNANT NEOPLASM OF UTERUS-PART UNS
180.0 MALIGNANT NEOPLASM OF ENDOCERVIX
180.1 MALIGNANT NEOPLASM OF EXOCERVIX
180.8 MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF CERVIX
180.9 MALIGNANT NEOPLASM OF CERVIX UTERI UNSPECIFIED SITE
181 MALIGNANT NEOPLASM OF PLACENTA
182.0 MALIGNANT NEOPLASM OF CORPUS UTERI EXCEPT ISTHMUS
182.1 MALIGNANT NEOPLASM OF ISTHMUS
182.8 MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF BODY OF UTERUS
183.0 MALIGNANT NEOPLASM OF OVARY
183.2 MALIGNANT NEOPLASM OF FALLOPIAN TUBE
183.3 MALIGNANT NEOPLASM OF BROAD LIGAMENT OF UTERUS
183.4 MALIGNANT NEOPLASM OF PARAMETRIUM
183.5 MALIGNANT NEOPLASM OF ROUND LIGAMENT OF UTERUS
183.8 MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF UTERINE ADNEXA
183.9 MALIGNANT NEOPLASM OF UTERINE ADNEXA UNSPECIFIED SITE
184.0 MALIGNANT NEOPLASM OF VAGINA
184.1 MALIGNANT NEOPLASM OF LABIA MAJORA
184.2 MALIGNANT NEOPLASM OF LABIA MINORA
184.3 MALIGNANT NEOPLASM OF CLITORIS
184.4 MALIGNANT NEOPLASM OF VULVA UNSPECIFIED SITE
184.8 MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF FEMALE GENITAL ORGANS
184.9 MALIGNANT NEOPLASM OF FEMALE GENITAL ORGAN SITE UNSPECIFIED
185 MALIGNANT NEOPLASM OF PROSTATE
186.0 MALIGNANT NEOPLASM OF UNDESCENDED TESTIS
186.9 MALIGNANT NEOPLASM OF OTHER AND UNSPECIFIED TESTIS
187.1 MALIGNANT NEOPLASM OF PREPUCE
187.2 MALIGNANT NEOPLASM OF GLANS PENIS
187.3 MALIGNANT NEOPLASM OF BODY OF PENIS
187.4 MALIGNANT NEOPLASM OF PENIS PART UNSPECIFIED
187.5 MALIGNANT NEOPLASM OF EPIDIDYMIS
187.6 MALIGNANT NEOPLASM OF SPERMATIC CORD
187.7 MALIGNANT NEOPLASM OF SCROTUM
187.8 MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF MALE GENITAL ORGANS
187.9 MALIGNANT NEOPLASM OF MALE GENITAL ORGAN SITE UNSPECIFIED
188.0 MALIGNANT NEOPLASM OF TRIGONE OF URINARY BLADDER
188.1 MALIGNANT NEOPLASM OF DOME OF URINARY BLADDER
188.2 MALIGNANT NEOPLASM OF LATERAL WALL OF URINARY BLADDER
188.3 MALIGNANT NEOPLASM OF ANTERIOR WALL OF URINARY BLADDER
188.4 MALIGNANT NEOPLASM OF POSTERIOR WALL OF URINARY BLADDER
188.5 MALIGNANT NEOPLASM OF BLADDER NECK
188.6 MALIGNANT NEOPLASM OF URETERIC ORIFICE
188.7 MALIGNANT NEOPLASM OF URACHUS
188.8 MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF BLADDER
188.9 MALIGNANT NEOPLASM OF BLADDER PART UNSPECIFIED
189.0 MALIGNANT NEOPLASM OF KIDNEY EXCEPT PELVIS
189.1 MALIGNANT NEOPLASM OF RENAL PELVIS
189.2 MALIGNANT NEOPLASM OF URETER
189.3 MALIGNANT NEOPLASM OF URETHRA
189.4 MALIGNANT NEOPLASM OF PARAURETHRAL GLANDS
189.8 MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF URINARY ORGANS
189.9 MALIGNANT NEOPLASM OF URINARY ORGAN SITE UNSPECIFIED
190.0 MALIGNANT NEOPLASM OF EYEBALL EXCEPT CONJUNCTIVA CORNEA RETINA AND CHOROID
190.1 MALIGNANT NEOPLASM OF ORBIT
190.2 MALIGNANT NEOPLASM OF LACRIMAL GLAND
190.3 MALIGNANT NEOPLASM OF CONJUNCTIVA
190.4 MALIGNANT NEOPLASM OF CORNEA
190.5 MALIGNANT NEOPLASM OF RETINA
190.6 MALIGNANT NEOPLASM OF CHOROID
190.7 MALIGNANT NEOPLASM OF LACRIMAL DUCT
190.8 MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF EYE
190.9 MALIGNANT NEOPLASM OF EYE PART UNSPECIFIED
191.0 MALIGNANT NEOPLASM OF CEREBRUM EXCEPT LOBES AND VENTRICLES
191.1 MALIGNANT NEOPLASM OF FRONTAL LOBE
191.2 MALIGNANT NEOPLASM OF TEMPORAL LOBE
191.3 MALIGNANT NEOPLASM OF PARIETAL LOBE
191.4 MALIGNANT NEOPLASM OF OCCIPITAL LOBE
191.5 MALIGNANT NEOPLASM OF VENTRICLES
191.6 MALIGNANT NEOPLASM OF CEREBELLUM NOS
191.7 MALIGNANT NEOPLASM OF BRAIN STEM
191.8 MALIGNANT NEOPLASM OF OTHER PARTS OF BRAIN
191.9 MALIGNANT NEOPLASM OF BRAIN UNSPECIFIED SITE
192.0 MALIGNANT NEOPLASM OF CRANIAL NERVES
192.1 MALIGNANT NEOPLASM OF CEREBRAL MENINGES
192.2 MALIGNANT NEOPLASM OF SPINAL CORD
192.3 MALIGNANT NEOPLASM OF SPINAL MENINGES
192.8 MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF NERVOUS SYSTEM
192.9 MALIGNANT NEOPLASM OF NERVOUS SYSTEM PART UNSPECIFIED
193 MALIGNANT NEOPLASM OF THYROID GLAND
194.0 MALIGNANT NEOPLASM OF ADRENAL GLAND
194.1 MALIGNANT NEOPLASM OF PARATHYROID GLAND
194.3 MALIGNANT NEOPLASM OF PITUITARY GLAND AND CRANIOPHARYNGEAL DUCT
194.4 MALIGNANT NEOPLASM OF PINEAL GLAND
194.5 MALIGNANT NEOPLASM OF CAROTID BODY
194.6 MALIGNANT NEOPLASM OF AORTIC BODY AND OTHER PARAGANGLIA
194.8 MALIGNANT NEOPLASM OF OTHER ENDOCRINE GLANDS AND RELATED STRUCTURES
194.9 MALIGNANT NEOPLASM OF ENDOCRINE GLAND SITE UNSPECIFIED
195.0 MALIGNANT NEOPLASM OF HEAD FACE AND NECK
195.1 MALIGNANT NEOPLASM OF THORAX
195.2 MALIGNANT NEOPLASM OF ABDOMEN
195.3 MALIGNANT NEOPLASM OF PELVIS
195.4 MALIGNANT NEOPLASM OF UPPER LIMB
195.5 MALIGNANT NEOPLASM OF LOWER LIMB
195.8 MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES
196.0 SECONDARY AND UNSPECIFIED MALIGNANT NEOPLASM OF LYMPH NODES OF HEAD FACE AND NECK
196.1 SECONDARY AND UNSPECIFIED MALIGNANT NEOPLASM OF INTRATHORACIC LYMPH NODES
196.2 SECONDARY AND UNSPECIFIED MALIGNANT NEOPLASM OF INTRA-ABDOMINAL LYMPH NODES
196.3 SECONDARY AND UNSPECIFIED MALIGNANT NEOPLASM OF LYMPH NODES OF AXILLA AND UPPER LIMB
196.5 SECONDARY AND UNSPECIFIED MALIGNANT NEOPLASM OF LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
196.6 SECONDARY AND UNSPECIFIED MALIGNANT NEOPLASM OF INTRAPELVIC LYMPH NODES
196.8 SECONDARY AND UNSPECIFIED MALIGNANT NEOPLASM OF LYMPH NODES OF MULTIPLE SITES
196.9 SECONDARY AND UNSPECIFIED MALIGNANT NEOPLASM OF LYMPH NODES SITE UNSPECIFIED
197.0 SECONDARY MALIGNANT NEOPLASM OF LUNG
197.1 SECONDARY MALIGNANT NEOPLASM OF MEDIASTINUM
197.2 SECONDARY MALIGNANT NEOPLASM OF PLEURA
197.3 SECONDARY MALIGNANT NEOPLASM OF OTHER RESPIRATORY ORGANS
197.4 SECONDARY MALIGNANT NEOPLASM OF SMALL INTESTINE INCLUDING DUODENUM
197.5 SECONDARY MALIGNANT NEOPLASM OF LARGE INTESTINE AND RECTUM
197.6 SECONDARY MALIGNANT NEOPLASM OF RETROPERITONEUM AND PERITONEUM
197.7 MALIGNANT NEOPLASM OF LIVER SECONDARY
197.8 SECONDARY MALIGNANT NEOPLASM OF OTHER DIGESTIVE ORGANS AND SPLEEN
198.0 SECONDARY MALIGNANT NEOPLASM OF KIDNEY
198.1 SECONDARY MALIGNANT NEOPLASM OF OTHER URINARY ORGANS
198.2 SECONDARY MALIGNANT NEOPLASM OF SKIN
198.3 SECONDARY MALIGNANT NEOPLASM OF BRAIN AND SPINAL CORD
198.4 SECONDARY MALIGNANT NEOPLASM OF OTHER PARTS OF NERVOUS SYSTEM
198.5 SECONDARY MALIGNANT NEOPLASM OF BONE AND BONE MARROW
198.6 SECONDARY MALIGNANT NEOPLASM OF OVARY
198.7 SECONDARY MALIGNANT NEOPLASM OF ADRENAL GLAND
198.81 SECONDARY MALIGNANT NEOPLASM OF BREAST
198.82 SECONDARY MALIGNANT NEOPLASM OF GENITAL ORGANS
198.89 SECONDARY MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES
199.0 DISSEMINATED MALIGNANT NEOPLASM
199.1 OTHER MALIGNANT NEOPLASM OF UNSPECIFIED SITE
199.2 MALIGNANT NEOPLASM ASSOCIATED WITH TRANSPLANT ORGAN
200.00 RETICULOSARCOMA UNSPECIFIED SITE
200.01 RETICULOSARCOMA INVOLVING LYMPH NODES OF HEAD FACE AND NECK
200.02 RETICULOSARCOMA INVOLVING INTRATHORACIC LYMPH NODES
200.03 RETICULOSARCOMA INVOLVING INTRA-ABDOMINAL LYMPH NODES
200.04 RETICULOSARCOMA INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB
200.05 RETICULOSARCOMA INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
200.06 RETICULOSARCOMA INVOLVING INTRAPELVIC LYMPH NODES
200.07 RETICULOSARCOMA INVOLVING SPLEEN
200.08 RETICULOSARCOMA INVOLVING LYMPH NODES OF MULTIPLE SITES
200.10 LYMPHOSARCOMA UNSPECIFIED SITE
200.11 LYMPHOSARCOMA INVOLVING LYMPH NODES OF HEAD FACE AND NECK
200.12 LYMPHOSARCOMA INVOLVING INTRATHORACIC LYMPH NODES
200.13 LYMPHOSARCOMA INVOLVING INTRA-ABDOMINAL LYMPH NODES
200.14 LYMPHOSARCOMA INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB
200.15 LYMPHOSARCOMA INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
200.16 LYMPHOSARCOMA INVOLVING INTRAPELVIC LYMPH NODES
200.17 LYMPHOSARCOMA INVOLVING SPLEEN
200.18 LYMPHOSARCOMA INVOLVING LYMPH NODES OF MULTIPLE SITES
200.20 BURKITT'S TUMOR OR LYMPHOMA UNSPECIFIED SITE
200.21 BURKITT'S TUMOR OR LYMPHOMA INVOLVING LYMPH NODES OF HEAD FACE AND NECK
200.22 BURKITT'S TUMOR OR LYMPHOMA INVOLVING INTRATHORACIC LYMPH NODES
200.23 BURKITT'S TUMOR OR LYMPHOMA INVOLVING INTRA-ABDOMINAL LYMPH NODES
200.24 BURKITT'S TUMOR OR LYMPHOMA INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB
200.25 BURKITT'S TUMOR OR LYMPHOMA INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
200.26 BURKITT'S TUMOR OR LYMPHOMA INVOLVING INTRAPELVIC LYMPH NODES
200.27 BURKITT'S TUMOR OR LYMPHOMA INVOLVING SPLEEN
200.28 BURKITT'S TUMOR OR LYMPHOMA INVOLVING LYMPH NODES OF MULTIPLE SITES
200.30 MARGINAL ZONE LYMPHOMA, UNSPECIFIED SITE, EXTRANODAL AND SOLID ORGAN SITES
200.31 MARGINAL ZONE LYMPHOMA,LYMPH NODES OF HEAD, FACE, AND NECK
200.32 MARGINAL ZONE LYMPHOMA,INTRATHORACIC LYMPH NODES
200.33 MARGINAL ZONE LYMPHOMA, INTRAABDOMINAL LYMPH NODES
200.34 MARGINAL ZONE LYMPHOMA, LYMPH NODES OF AXILLA AND UPPER LIMB
200.35 MARGINAL ZONE LYMPHOMA, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
200.36 MARGINAL ZONE LYMPHOMA, INTRAPELVIC LYMPH NODES
200.37 MARGINAL ZONE LYMPHOMA, SPLEEN
200.38 MARGINAL ZONE LYMPHOMA, LYMPH NODES OF MULTIPLE SITES
200.40 MANTLE CELL LYMPHOMA, UNSPECIFIED SITE, EXTRANODAL AND SOLID ORGAN SITES
200.41 MANTLE CELL LYMPHOMA, LYMPH NODES OF HEAD, FACE, AND NECK
200.42 MANTLE CELL LYMPHOMA, INTRATHORACIC LYMPH NODES
200.43 MANTLE CELL LYMPHOMA, INTRA-ABDOMINAL LYMPH NODES
200.44 MANTLE CELL LYMPHOMA, LYMPH NODES OF AXILLA AND UPPER LIMB
200.45 MANTLE CELL LYMPHOMA, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
200.46 MANTLE CELL LYMPHOMA, INTRAPELVIC LYMPH NODES
200.47 MANTLE CELL LYMPHOMA, SPLEEN
200.48 MANTLE CELL LYMPHOMA, LYMPH NODES OF MULTIPLE SITES
200.50 PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA, UNSPECIFIED SITE, EXTRANODAL AND SOLID ORGAN SITES
200.51 PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA, LYMPH NODES OF HEAD, FACE, AND NECK
200.52 PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA, INTRATHORACIC LYMPH NODES
200.53 PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA, INTRA-ABDOMINAL LYMPH NODES
200.54 PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA, LYMPH NODES OF AXILLA AND UPPER LIMB
200.55 PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
200.56 PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA, INTRAPELVIC LYMPH NODES
200.57 PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA, SPLEEN
200.58 PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA, LYMPH NODES OF MULTIPLE SITES
200.60 ANAPLASTIC LARGE CELL LYMPHOMA, UNSPECIFIED SITE, EXTRANODAL AND SOLID ORGAN SITES
200.61 ANAPLASTIC LARGE CELL LYMPHOMA, LYMPH NODES OF HEAD, FACE, AND NECK
200.62 ANAPLASTIC LARGE CELL LYMPHOMA, INTRATHORACIC LYMPH NODES
200.63 ANAPLASTIC LARGE CELL LYMPHOMA, INTRA-ABDOMINAL LYMPH NODES
200.64 ANAPLASTIC LARGE CELL LYMPHOMA, LYMPH NODES OF AXILLA AND UPPER LIMB
200.65 ANAPLASTIC LARGE CELL LYMPHOMA, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
200.66 ANAPLASTIC LARGE CELL LYMPHOMA, INTRAPELVIC LYMPH NODES
200.67 ANAPLASTIC LARGE CELL LYMPHOMA, SPLEEN
200.68 ANAPLASTIC LARGE CELL LYMPHOMA, LYMPH NODES OF MULTIPLE SITES
200.70 LARGE CELL LYMPHOMA, UNSPECIFIED SITE, EXTRANODAL AND SOLID ORGAN SITES
200.71 LARGE CELL LYMPHOMA, LYMPH NODES OF HEAD, FACE, AND NECK
200.72 LARGE CELL LYMPHOMA, INTRATHORACIC LYMPH NODES
200.73 LARGE CELL LYMPHOMA, INTRA-ABDOMINAL LYMPH NODES
200.74 LARGE CELL LYMPHOMA, LYMPH NODES OF AXILLA AND UPPER LIMB
200.75 LARGE CELL LYMPHOMA, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
200.76 LARGE CELL LYMPHOMA, INTRAPELVIC LYMPH NODES
200.77 LARGE CELL LYMPHOMA, SPLEEN
200.78 LARGE CELL LYMPHOMA, LYMPH NODES OF MULTIPLE SITES
200.80 OTHER NAMED VARIANTS OF LYMPHOSARCOMA AND RETICULOSARCOMA UNSPECIFIED SITE
200.81 OTHER NAMED VARIANTS OF LYMPHOSARCOMA AND RETICULOSARCOMA INVOLVING LYMPH NODES OF HEAD FACE AND NECK
200.82 OTHER NAMED VARIANTS OF LYMPHOSARCOMA AND RETICULOSARCOMA INVOLVING INTRATHORACIC LYMPH NODES
200.83 OTHER NAMED VARIANTS OF LYMPHOSARCOMA AND RETICULOSARCOMA INVOLVING INTRA-ABDOMINAL LYMPH NODES
200.84 OTHER NAMED VARIANTS OF LYMPHOSARCOMA AND RETICULOSARCOMA INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB
200.85 OTHER NAMED VARIANTS OF LYMPHOSARCOMA AND RETICULOSARCOMA INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
200.86 OTHER NAMED VARIANTS OF LYMPHOSARCOMA AND RETICULOSARCOMA INVOLVING INTRAPELVIC LYMPH NODES
200.87 OTHER NAMED VARIANTS OF LYMPHOSARCOMA AND RETICULOSARCOMA INVOLVING SPLEEN
200.88 OTHER NAMED VARIANTS OF LYMPHOSARCOMA AND RETICULOSARCOMA INVOLVING LYMPH NODES OF MULTIPLE SITES
201.00 HODGKIN'S PARAGRANULOMA UNSPECIFIED SITE
201.01 HODGKIN'S PARAGRANULOMA INVOLVING LYMPH NODES OF HEAD FACE AND NECK
201.02 HODGKIN'S PARAGRANULOMA INVOLVING INTRATHORACIC LYMPH NODES
201.03 HODGKIN'S PARAGRANULOMA INVOLVING INTRA-ABDOMINAL LYMPH NODES
201.04 HODGKIN'S PARAGRANULOMA INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB
201.05 HODGKIN'S PARAGRANULOMA INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
201.06 HODGKIN'S PARAGRANULOMA INVOLVING INTRAPELVIC LYMPH NODES
201.07 HODGKIN'S PARAGRANULOMA INVOLVING SPLEEN
201.08 HODGKIN'S PARAGRANULOMA INVOLVING LYMPH NODES OF MULTIPLE SITES
201.10 HODGKIN'S GRANULOMA UNSPECIFIED SITE
201.11 HODGKIN'S GRANULOMA INVOLVING LYMPH NODES OF HEAD FACE AND NECK
201.12 HODGKIN'S GRANULOMA INVOLVING INTRATHORACIC LYMPH NODES
201.13 HODGKIN'S GRANULOMA INVOLVING INTRA-ABDOMINAL LYMPH NODES
201.14 HODGKIN'S GRANULOMA INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB
201.15 HODGKIN'S GRANULOMA INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
201.16 HODGKIN'S GRANULOMA INVOLVING INTRAPELVIC LYMPH NODES
201.17 HODGKIN'S GRANULOMA INVOLVING SPLEEN
201.18 HODGKIN'S GRANULOMA INVOLVING LYMPH NODES OF MULTIPLE SITES
201.20 HODGKIN'S SARCOMA UNSPECIFIED SITE
201.21 HODGKIN'S SARCOMA INVOLVING LYMPH NODES OF HEAD FACE AND NECK
201.22 HODGKIN'S SARCOMA INVOLVING INTRATHORACIC LYMPH NODES
201.23 HODGKIN'S SARCOMA INVOLVING INTRA-ABDOMINAL LYMPH NODES
201.24 HODGKIN'S SARCOMA INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB
201.25 HODGKIN'S SARCOMA INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
201.26 HODGKIN'S SARCOMA INVOLVING INTRAPELVIC LYMPH NODES
201.27 HODGKIN'S SARCOMA INVOLVING SPLEEN
201.28 HODGKIN'S SARCOMA INVOLVING LYMPH NODES OF MULTIPLE SITES
201.40 HODGKIN'S DISEASE LYMPHOCYTIC-HISTIOCYTIC PREDOMINANCE UNSPECIFIED SITE
201.41 HODGKIN'S DISEASE LYMPHOCYTIC-HISTIOCYTIC PREDOMINANCE INVOLVING LYMPH NODES OF HEAD FACE AND NECK
201.42 HODGKIN'S DISEASE LYMPHOCYTIC-HISTIOCYTIC PREDOMINANCE INVOLVING INTRATHORACIC LYMPH NODES
201.43 HODGKIN'S DISEASE LYMPHOCYTIC-HISTIOCYTIC PREDOMINANCE INVOLVING INTRA-ABDOMINAL LYMPH NODES
201.44 HODGKIN'S DISEASE LYMPHOCYTIC-HISTIOCYTIC PREDOMINANCE INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB
201.45 HODGKIN'S DISEASE LYMPHOCYTIC-HISTIOCYTIC PREDOMINANCE INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
201.46 HODGKIN'S DISEASE LYMPHOCYTIC-HISTIOCYTIC PREDOMINANCE INVOLVING INTRAPELVIC LYMPH NODES
201.47 HODGKIN'S DISEASE LYMPHOCYTIC-HISTIOCYTIC PREDOMINANCE INVOLVING SPLEEN
201.48 HODGKIN'S DISEASE LYMPHOCYTIC-HISTIOCYTIC PREDOMINANCE INVOLVING LYMPH NODES OF MULTIPLE SITES
201.50 HODGKIN'S DISEASE NODULAR SCLEROSIS UNSPECIFIED SITE
201.51 HODGKIN'S DISEASE NODULAR SCLEROSIS INVOLVING LYMPH NODES OF HEAD FACE AND NECK
201.52 HODGKIN'S DISEASE NODULAR SCLEROSIS INVOLVING INTRATHORACIC LYMPH NODES
201.53 HODGKIN'S DISEASE NODULAR SCLEROSIS INVOLVING INTRA-ABDOMINAL LYMPH NODES
201.54 HODGKIN'S DISEASE NODULAR SCLEROSIS INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB
201.55 HODGKIN'S DISEASE NODULAR SCLEROSIS INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
201.56 HODGKIN'S DISEASE NODULAR SCLEROSIS INVOLVING INTRAPELVIC LYMPH NODES
201.57 HODGKIN'S DISEASE NODULAR SCLEROSIS INVOLVING SPLEEN
201.58 HODGKIN'S DISEASE NODULAR SCLEROSIS INVOLVING LYMPH NODES OF MULTIPLE SITES
201.60 HODGKIN'S DISEASE MIXED CELLULARITY UNSPECIFIED SITE
201.61 HODGKIN'S DISEASE MIXED CELLULARITY INVOLVING LYMPH NODES OF HEAD FACE AND NECK
201.62 HODGKIN'S DISEASE MIXED CELLULARITY INVOLVING INTRATHORACIC LYMPH NODES
201.63 HODGKIN'S DISEASE MIXED CELLULARITY INVOLVING INTRA-ABDOMINAL LYMPH NODES
201.64 HODGKIN'S DISEASE MIXED CELLULARITY INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB
201.65 HODGKIN'S DISEASE MIXED CELLULARITY INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
201.66 HODGKIN'S DISEASE MIXED CELLULARITY INVOLVING INTRAPELVIC LYMPH NODES
201.67 HODGKIN'S DISEASE MIXED CELLULARITY INVOLVING SPLEEN
201.68 HODGKIN'S DISEASE MIXED CELLULARITY INVOLVING LYMPH NODES OF MULTIPLE SITES
201.70 HODGKIN'S DISEASE LYMPHOCYTIC DEPLETION UNSPECIFIED SITE
201.71 HODGKIN'S DISEASE LYMPHOCYTIC DEPLETION INVOLVING LYMPH NODES OF HEAD FACE AND NECK
201.72 HODGKIN'S DISEASE LYMPHOCYTIC DEPLETION INVOLVING INTRATHORACIC LYMPH NODES
201.73 HODGKIN'S DISEASE LYMPHOCYTIC DEPLETION INVOLVING INTRA-ABDOMINAL LYMPH NODES
201.74 HODGKIN'S DISEASE LYMPHOCYTIC DEPLETION INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB
201.75 HODGKIN'S DISEASE LYMPHOCYTIC DEPLETION INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
201.76 HODGKIN'S DISEASE LYMPHOCYTIC DEPLETION INVOLVING INTRAPELVIC LYMPH NODES
201.77 HODGKIN'S DISEASE LYMPHOCYTIC DEPLETION INVOLVING SPLEEN
201.78 HODGKIN'S DISEASE LYMPHOCYTIC DEPLETION INVOLVING LYMPH NODES OF MULTIPLE SITES
201.90 HODGKIN'S DISEASE UNSPECIFIED TYPE UNSPECIFIED SITE
201.91 HODGKIN'S DISEASE UNSPECIFIED TYPE INVOLVING LYMPH NODES OF HEAD FACE AND NECK
201.92 HODGKIN'S DISEASE UNSPECIFIED TYPE INVOLVING INTRATHORACIC LYMPH NODES
201.93 HODGKIN'S DISEASE UNSPECIFIED TYPE INVOLVING INTRA-ABDOMINAL LYMPH NODES
201.94 HODGKIN'S DISEASE UNSPECIFIED TYPE INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB
201.95 HODGKIN'S DISEASE UNSPECIFIED TYPE INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
201.96 HODGKIN'S DISEASE UNSPECIFIED TYPE INVOLVING INTRAPELVIC LYMPH NODES
201.97 HODGKIN'S DISEASE UNSPECIFIED TYPE INVOLVING SPLEEN
201.98 HODGKIN'S DISEASE UNSPECIFIED TYPE INVOLVING LYMPH NODES OF MULTIPLE SITES
202.00 NODULAR LYMPHOMA UNSPECIFIED SITE
202.01 NODULAR LYMPHOMA INVOLVING LYMPH NODES OF HEAD FACE AND NECK
202.02 NODULAR LYMPHOMA INVOLVING INTRATHORACIC LYMPH NODES
202.03 NODULAR LYMPHOMA INVOLVING INTRA-ABDOMINAL LYMPH NODES
202.04 NODULAR LYMPHOMA INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB
202.05 NODULAR LYMPHOMA INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
202.06 NODULAR LYMPHOMA INVOLVING INTRAPELVIC LYMPH NODES
202.07 NODULAR LYMPHOMA INVOLVING SPLEEN
202.08 NODULAR LYMPHOMA INVOLVING LYMPH NODES OF MULTIPLE SITES
202.10 MYCOSIS FUNGOIDES UNSPECIFIED SITE
202.11 MYCOSIS FUNGOIDES INVOLVING LYMPH NODES OF HEAD FACE AND NECK
202.12 MYCOSIS FUNGOIDES INVOLVING INTRATHORACIC LYMPH NODES
202.13 MYCOSIS FUNGOIDES INVOLVING INTRA-ABDOMINAL LYMPH NODES
202.14 MYCOSIS FUNGOIDES INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB
202.15 MYCOSIS FUNGOIDES INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
202.16 MYCOSIS FUNGOIDES INVOLVING INTRAPELVIC LYMPH NODES
202.17 MYCOSIS FUNGOIDES INVOLVING SPLEEN
202.18 MYCOSIS FUNGOIDES INVOLVING LYMPH NODES OF MULTIPLE SITES
202.20 SEZARY'S DISEASE UNSPECIFIED SITE
202.21 SEZARY'S DISEASE INVOLVING LYMPH NODES OF HEAD FACE AND NECK
202.22 SEZARY'S DISEASE INVOLVING INTRATHORACIC LYMPH NODES
202.23 SEZARY'S DISEASE INVOLVING INTRA-ABDOMINAL LYMPH NODES
202.24 SEZARY'S DISEASE INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB
202.25 SEZARY'S DISEASE INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
202.26 SEZARY'S DISEASE INVOLVING INTRAPELVIC LYMPH NODES
202.27 SEZARY'S DISEASE INVOLVING SPLEEN
202.28 SEZARY'S DISEASE INVOLVING LYMPH NODES OF MULTIPLE SITES
202.30 MALIGNANT HISTIOCYTOSIS UNSPECIFIED SITE
202.31 MALIGNANT HISTIOCYTOSIS INVOLVING LYMPH NODES OF HEAD FACE AND NECK
202.32 MALIGNANT HISTIOCYTOSIS INVOLVING INTRATHORACIC LYMPH NODES
202.33 MALIGNANT HISTIOCYTOSIS INVOLVING INTRA-ABDOMINAL LYMPH NODES
202.34 MALIGNANT HISTIOCYTOSIS INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB
202.35 MALIGNANT HISTIOCYTOSIS INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
202.36 MALIGNANT HISTIOCYTOSIS INVOLVING INTRAPELVIC LYMPH NODES
202.37 MALIGNANT HISTIOCYTOSIS INVOLVING SPLEEN
202.38 MALIGNANT HISTIOCYTOSIS INVOLVING LYMPH NODES OF MULTIPLE SITES
202.40 LEUKEMIC RETICULOENDOTHELIOSIS UNSPECIFIED SITE
202.41 LEUKEMIC RETICULOENDOTHELIOSIS INVOLVING LYMPH NODES OF HEAD FACE AND NECK
202.42 LEUKEMIC RETICULOENDOTHELIOSIS INVOLVING INTRATHORACIC LYMPH NODES
202.43 LEUKEMIC RETICULOENDOTHELIOSIS INVOLVING INTRA-ABDOMINAL LYMPH NODES
202.44 LEUKEMIC RETICULOENDOTHELIOSIS INVOLVING LYMPH NODES OF AXILLA AND UPPER ARM
202.45 LEUKEMIC RETICULOENDOTHELIOSIS INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
202.46 LEUKEMIC RETICULOENDOTHELIOSIS INVOLVING INTRAPELVIC LYMPH NODES
202.47 LEUKEMIC RETICULOENDOTHELIOSIS INVOLVING SPLEEN
202.48 LEUKEMIC RETICULOENDOTHELIOSIS INVOLVING LYMPH NODES OF MULTIPLE SITES
202.50 LETTERER-SIWE DISEASE UNSPECIFIED SITE
202.51 LETTERER-SIWE DISEASE INVOLVING LYMPH NODES OF HEAD FACE AND NECK
202.52 LETTERER-SIWE DISEASE INVOLVING INTRATHORACIC LYMPH NODES
202.53 LETTERER-SIWE DISEASE INVOLVING INTRA-ABDOMINAL LYMPH NODES
202.54 LETTERER-SIWE DISEASE INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB
202.55 LETTERER-SIWE DISEASE INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
202.56 LETTERER-SIWE DISEASE INVOLVING INTRAPELVIC LYMPH NODES
202.57 LETTERER-SIWE DISEASE INVOLVING SPLEEN
202.58 LETTERER-SIWE DISEASE INVOLVING LYMPH NODES OF MULTIPLE SITES
202.60 MALIGNANT MAST CELL TUMORS UNSPECIFIED SITE
202.61 MALIGNANT MAST CELL TUMORS INVOLVING LYMPH NODES OF HEAD FACE AND NECK
202.62 MALIGNANT MAST CELL TUMORS INVOLVING INTRATHORACIC LYMPH NODES
202.63 MALIGNANT MAST CELL TUMORS INVOLVING INTRA-ABDOMINAL LYMPH NODES
202.64 MALIGNANT MAST CELL TUMORS INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB
202.65 MALIGNANT MAST CELL TUMORS INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
202.66 MALIGNANT MAST CELL TUMORS INVOLVING INTRAPELVIC LYMPH NODES
202.67 MALIGNANT MAST CELL TUMORS INVOLVING SPLEEN
202.68 MALIGNANT MAST CELL TUMORS INVOLVING LYMPH NODES OF MULTIPLE SITES
202.70 PERIPHERAL T CELL LYMPHOMA, UNSPECIFIED SITE, EXTRANODAL AND SOLID ORGAN SITES
202.71 PERIPHERAL T CELL LYMPHOMA, LYMPH NODES OF HEAD, FACE, AND NECK
202.72 PERIPHERAL T CELL LYMPHOMA, INTRATHORACIC LYMPH NODES
202.73 PERIPHERAL T CELL LYMPHOMA, INTRA-ABDOMINAL LYMPH NODES
202.74 PERIPHERAL T CELL LYMPHOMA, LYMPH NODES OF AXILLA AND UPPER LIMB
202.75 PERIPHERAL T CELL LYMPHOMA, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
202.76 PERIPHERAL T CELL LYMPHOMA, INTRAPELVIC LYMPH NODES
202.77 PERIPHERAL T CELL LYMPHOMA, SPLEEN
202.78 PERIPHERAL T CELL LYMPHOMA, LYMPH NODES OF MULTIPLE SITES
202.80 OTHER MALIGNANT LYMPHOMAS UNSPECIFIED SITE
202.81 OTHER MALIGNANT LYMPHOMAS INVOLVING LYMPH NODES OF HEAD FACE AND NECK
202.82 OTHER MALIGNANT LYMPHOMAS INVOLVING INTRATHORACIC LYMPH NODES
202.83 OTHER MALIGNANT LYMPHOMAS INVOLVING INTRA-ABDOMINAL LYMPH NODES
202.84 OTHER MALIGNANT LYMPHOMAS INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB
202.85 OTHER MALIGNANT LYMPHOMAS INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
202.86 OTHER MALIGNANT LYMPHOMAS INVOLVING INTRAPELVIC LYMPH NODES
202.87 OTHER MALIGNANT LYMPHOMAS INVOLVING SPLEEN
202.88 OTHER MALIGNANT LYMPHOMAS INVOLVING LYMPH NODES OF MULTIPLE SITES
202.90 OTHER AND UNSPECIFIED MALIGNANT NEOPLASMS OF LYMPHOID AND HISTIOCYTIC TISSUE UNSPECIFIED SITE
202.91 OTHER AND UNSPECIFIED MALIGNANT NEOPLASMS OF LYMPHOID AND HISTIOCYTIC TISSUE INVOLVING LYMPH NODES OF HEAD FACE AND NECK
202.92 OTHER AND UNSPECIFIED MALIGNANT NEOPLASMS OF LYMPHOID AND HISTIOCYTIC TISSUE INVOLVING INTRATHORACIC LYMPH NODES
202.93 OTHER AND UNSPECIFIED MALIGNANT NEOPLASMS OF LYMPHOID AND HISTIOCYTIC TISSUE INVOLVING INTRA-ABDOMINAL LYMPH NODES
202.94 OTHER AND UNSPECIFIED MALIGNANT NEOPLASMS OF LYMPHOID AND HISTIOCYTIC TISSUE INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB
202.95 OTHER AND UNSPECIFIED MALIGNANT NEOPLASMS OF LYMPHOID AND HISTIOCYTIC TISSUE INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
202.96 OTHER AND UNSPECIFIED MALIGNANT NEOPLASMS OF LYMPHOID AND HISTIOCYTIC TISSUE INVOLVING INTRAPELVIC LYMPH NODES
202.97 OTHER AND UNSPECIFIED MALIGNANT NEOPLASMS OF LYMPHOID AND HISTIOCYTIC TISSUE INVOLVING SPLEEN
202.98 OTHER AND UNSPECIFIED MALIGNANT NEOPLASMS OF LYMPHOID AND HISTIOCYTIC TISSUE INVOLVING LYMPH NODES OF MULTIPLE SITES
203.00 MULTIPLE MYELOMA, WITHOUT MENTION OF HAVING ACHIEVED REMISSION
203.01 MULTIPLE MYELOMA IN REMISSION
203.02 MULTIPLE MYELOMA, IN RELAPSE
203.10 PLASMA CELL LEUKEMIA, WITHOUT MENTION OF HAVING ACHIEVED REMISSION
203.11 PLASMA CELL LEUKEMIA IN REMISSION
203.12 PLASMA CELL LEUKEMIA, IN RELAPSE
203.80 OTHER IMMUNOPROLIFERATIVE NEOPLASMS, WITHOUT MENTION OF HAVING ACHIEVED REMISSION
203.81 OTHER IMMUNOPROLIFERATIVE NEOPLASMS IN REMISSION
203.82 OTHER IMMUNOPROLIFERATIVE NEOPLASMS, IN RELAPSE
204.00 ACUTE LYMPHOID LEUKEMIA, WITHOUT MENTION OF HAVING ACHIEVED REMISSION
204.01 LYMPHOID LEUKEMIA ACUTE IN REMISSION
204.02 ACUTE LYMPHOID LEUKEMIA, IN RELAPSE
204.10 CHRONIC LYMPHOID LEUKEMIA, WITHOUT MENTION OF HAVING ACHIEVED REMISSION
204.11 LYMPHOID LEUKEMIA CHRONIC IN REMISSION
204.12 CHRONIC LYMPHOID LEUKEMIA, IN RELAPSE
204.20 SUBACUTE LYMPHOID LEUKEMIA, WITHOUT MENTION OF HAVING ACHIEVED REMISSION
204.21 LYMPHOID LEUKEMIA SUBACUTE IN REMISSION
204.22 SUBACUTE LYMPHOID LEUKEMIA, IN RELAPSE
204.80 OTHER LYMPHOID LEUKEMIA, WITHOUT MENTION OF HAVING ACHIEVED REMISSION
204.81 OTHER LYMPHOID LEUKEMIA IN REMISSION
204.82 OTHER LYMPHOID LEUKEMIA, IN RELAPSE
204.90 UNSPECIFIED LYMPHOID LEUKEMIA, WITHOUT MENTION OF HAVING ACHIEVED REMISSION
204.91 UNSPECIFIED LYMPHOID LEUKEMIA IN REMISSION
204.92 UNSPECIFIED LYMPHOID LEUKEMIA, IN RELAPSE
209.00 MALIGNANT CARCINOID TUMOR OF THE SMALL INTESTINE, UNSPECIFIED PORTION
209.01 MALIGNANT CARCINOID TUMOR OF THE DUODENUM
209.02 MALIGNANT CARCINOID TUMOR OF THE JEJUNUM
209.03 MALIGNANT CARCINOID TUMOR OF THE ILEUM
209.10 MALIGNANT CARCINOID TUMOR OF THE LARGE INTESTINE, UNSPECIFIED PORTION
209.11 MALIGNANT CARCINOID TUMOR OF THE APPENDIX
209.12 MALIGNANT CARCINOID TUMOR OF THE CECUM
209.13 MALIGNANT CARCINOID TUMOR OF THE ASCENDING COLON
209.14 MALIGNANT CARCINOID TUMOR OF THE TRANSVERSE COLON
209.15 MALIGNANT CARCINOID TUMOR OF THE DESCENDING COLON
209.16 MALIGNANT CARCINOID TUMOR OF THE SIGMOID COLON
209.17 MALIGNANT CARCINOID TUMOR OF THE RECTUM
209.20 MALIGNANT CARCINOID TUMOR OF UNKNOWN PRIMARY SITE
209.21 MALIGNANT CARCINOID TUMOR OF THE BRONCHUS AND LUNG
209.22 MALIGNANT CARCINOID TUMOR OF THE THYMUS
209.23 MALIGNANT CARCINOID TUMOR OF THE STOMACH
209.24 MALIGNANT CARCINOID TUMOR OF THE KIDNEY
209.25 MALIGNANT CARCINOID TUMOR OF FOREGUT, NOT OTHERWISE SPECIFIED
209.26 MALIGNANT CARCINOID TUMOR OF MIDGUT, NOT OTHERWISE SPECIFIED
209.27 MALIGNANT CARCINOID TUMOR OF HINDGUT, NOT OTHERWISE SPECIFIED
209.29 MALIGNANT CARCINOID TUMOR OF OTHER SITES
209.30 MALIGNANT POORLY DIFFERENTIATED NEUROENDOCRINE CARCINOMA, ANY SITE
209.31 MERKEL CELL CARCINOMA OF THE FACE
209.32 MERKEL CELL CARCINOMA OF THE SCALP AND NECK
209.33 MERKEL CELL CARCINOMA OF THE UPPER LIMB
209.34 MERKEL CELL CARCINOMA OF THE LOWER LIMB
209.35 MERKEL CELL CARCINOMA OF THE TRUNK
209.36 MERKEL CELL CARCINOMA OF OTHER SITES
209.70 SECONDARY NEUROENDOCRINE TUMOR, UNSPECIFIED SITE
209.71 SECONDARY NEUROENDOCRINE TUMOR OF DISTANT LYMPH NODES
209.72 SECONDARY NEUROENDOCRINE TUMOR OF LIVER
209.73 SECONDARY NEUROENDOCRINE TUMOR OF BONE
209.74 SECONDARY NEUROENDOCRINE TUMOR OF PERITONEUM
209.75 SECONDARY MERKEL CELL CARCINOMA
209.79 SECONDARY NEUROENDOCRINE TUMOR OF OTHER SITES
230.0 CARCINOMA IN SITU OF LIP ORAL CAVITY AND PHARYNX
230.1 CARCINOMA IN SITU OF ESOPHAGUS
230.2 CARCINOMA IN SITU OF STOMACH
230.3 CARCINOMA IN SITU OF COLON
230.4 CARCINOMA IN SITU OF RECTUM
230.5 CARCINOMA IN SITU OF ANAL CANAL
230.6 CARCINOMA IN SITU OF ANUS UNSPECIFIED
230.7 CARCINOMA IN SITU OF OTHER AND UNSPECIFIED PARTS OF INTESTINE
230.8 CARCINOMA IN SITU OF LIVER AND BILIARY SYSTEM
230.9 CARCINOMA IN SITU OF OTHER AND UNSPECIFIED DIGESTIVE ORGANS
231.0 CARCINOMA IN SITU OF LARYNX
231.1 CARCINOMA IN SITU OF TRACHEA
231.2 CARCINOMA IN SITU OF BRONCHUS AND LUNG
231.8 CARCINOMA IN SITU OF OTHER SPECIFIED PARTS OF RESPIRATORY SYSTEM
231.9 CARCINOMA IN SITU OF RESPIRATORY SYSTEM PART UNSPECIFIED
232.0 CARCINOMA IN SITU OF SKIN OF LIP
232.1 CARCINOMA IN SITU OF EYELID INCLUDING CANTHUS
232.2 CARCINOMA IN SITU OF SKIN OF EAR AND EXTERNAL AUDITORY CANAL
232.3 CARCINOMA IN SITU OF SKIN OF OTHER AND UNSPECIFIED PARTS OF FACE
232.4 CARCINOMA IN SITU OF SCALP AND SKIN OF NECK
232.5 CARCINOMA IN SITU OF SKIN OF TRUNK EXCEPT SCROTUM
232.6 CARCINOMA IN SITU OF SKIN OF UPPER LIMB INCLUDING SHOULDER
232.7 CARCINOMA IN SITU OF SKIN OF LOWER LIMB INCLUDING HIP
232.8 CARCINOMA IN SITU OF OTHER SPECIFIED SITES OF SKIN
232.9 CARCINOMA IN SITU OF SKIN SITE UNSPECIFIED
233.0 CARCINOMA IN SITU OF BREAST
233.1 CARCINOMA IN SITU OF CERVIX UTERI
233.2 CARCINOMA IN SITU OF OTHER AND UNSPECIFIED PARTS OF UTERUS
233.30 CARCINOMA IN SITU, UNSPECIFIED FEMALE GENITAL ORGAN
233.31 CARCINOMA IN SITU, VAGINA
233.32 CARCINOMA IN SITU, VULVA
233.39 CARCINOMA IN SITU, OTHER FEMALE GENITAL ORGAN
233.4 CARCINOMA IN SITU OF PROSTATE
233.5 CARCINOMA IN SITU OF PENIS
233.6 CARCINOMA IN SITU OF OTHER AND UNSPECIFIED MALE GENITAL ORGANS
233.7 CARCINOMA IN SITU OF BLADDER
233.9 CARCINOMA IN SITU OF OTHER AND UNSPECIFIED URINARY ORGANS
234.0 CARCINOMA IN SITU OF EYE
234.8 CARCINOMA IN SITU OF OTHER SPECIFIED SITES
234.9 CARCINOMA IN SITU SITE UNSPECIFIED
235.0 NEOPLASM OF UNCERTAIN BEHAVIOR OF MAJOR SALIVARY GLANDS
235.1 NEOPLASM OF UNCERTAIN BEHAVIOR OF LIP ORAL CAVITY AND PHARYNX
235.2 NEOPLASM OF UNCERTAIN BEHAVIOR OF STOMACH INTESTINES AND RECTUM
235.3 NEOPLASM OF UNCERTAIN BEHAVIOR OF LIVER AND BILIARY PASSAGES
235.4 NEOPLASM OF UNCERTAIN BEHAVIOR OF RETROPERITONEUM AND PERITONEUM
235.5 NEOPLASM OF UNCERTAIN BEHAVIOR OF OTHER AND UNSPECIFIED DIGESTIVE ORGANS
235.6 NEOPLASM OF UNCERTAIN BEHAVIOR OF LARYNX
235.7 NEOPLASM OF UNCERTAIN BEHAVIOR OF TRACHEA BRONCHUS AND LUNG
235.8 NEOPLASM OF UNCERTAIN BEHAVIOR OF PLEURA THYMUS AND MEDIASTINUM
235.9 NEOPLASM OF UNCERTAIN BEHAVIOR OF OTHER AND UNSPECIFIED RESPIRATORY ORGANS
236.0 NEOPLASM OF UNCERTAIN BEHAVIOR OF UTERUS
236.1 NEOPLASM OF UNCERTAIN BEHAVIOR OF PLACENTA
236.2 NEOPLASM OF UNCERTAIN BEHAVIOR OF OVARY
236.3 NEOPLASM OF UNCERTAIN BEHAVIOR OF OTHER AND UNSPECIFIED FEMALE GENITAL ORGANS
236.4 NEOPLASM OF UNCERTAIN BEHAVIOR OF TESTIS
236.5 NEOPLASM OF UNCERTAIN BEHAVIOR OF PROSTATE
236.6 NEOPLASM OF UNCERTAIN BEHAVIOR OF OTHER AND UNSPECIFIED MALE GENITAL ORGANS
236.7 NEOPLASM OF UNCERTAIN BEHAVIOR OF BLADDER
236.90 NEOPLASM OF UNCERTAIN BEHAVIOR OF URINARY ORGAN UNSPECIFIED
236.91 NEOPLASM OF UNCERTAIN BEHAVIOR OF KIDNEY AND URETER
236.99 NEOPLASM OF UNCERTAIN BEHAVIOR OF OTHER AND UNSPECIFIED URINARY ORGANS
237.0 NEOPLASM OF UNCERTAIN BEHAVIOR OF PITUITARY GLAND AND CRANIOPHARYNGEAL DUCT
237.1 NEOPLASM OF UNCERTAIN BEHAVIOR OF PINEAL GLAND
237.2 NEOPLASM OF UNCERTAIN BEHAVIOR OF ADRENAL GLAND
237.3 NEOPLASM OF UNCERTAIN BEHAVIOR OF PARAGANGLIA
237.4 NEOPLASM OF UNCERTAIN BEHAVIOR OF OTHER AND UNSPECIFIED ENDOCRINE GLANDS
237.5 NEOPLASM OF UNCERTAIN BEHAVIOR OF BRAIN AND SPINAL CORD
237.6 NEOPLASM OF UNCERTAIN BEHAVIOR OF MENINGES
237.70 NEUROFIBROMATOSIS UNSPECIFIED
237.71 NEUROFIBROMATOSIS TYPE 1 VON RECKLINGHAUSEN'S DISEASE
237.72 NEUROFIBROMATOSIS TYPE 2 ACOUSTIC NEUROFIBROMATOSIS
237.73 SCHWANNOMATOSIS
237.79 OTHER NEUROFIBROMATOSIS
237.9 NEOPLASM OF UNCERTAIN BEHAVIOR OF OTHER AND UNSPECIFIED PARTS OF NERVOUS SYSTEM
238.0 NEOPLASM OF UNCERTAIN BEHAVIOR OF BONE AND ARTICULAR CARTILAGE
238.1 NEOPLASM OF UNCERTAIN BEHAVIOR OF CONNECTIVE AND OTHER SOFT TISSUE
238.2 NEOPLASM OF UNCERTAIN BEHAVIOR OF SKIN
238.3 NEOPLASM OF UNCERTAIN BEHAVIOR OF BREAST
238.4 POLYCYTHEMIA VERA
238.5 NEOPLASM OF UNCERTAIN BEHAVIOR OF HISTIOCYTIC AND MAST CELLS
238.6 NEOPLASM OF UNCERTAIN BEHAVIOR OF PLASMA CELLS
238.8 NEOPLASM OF UNCERTAIN BEHAVIOR OF OTHER SPECIFIED SITES
238.9 NEOPLASM OF UNCERTAIN BEHAVIOR SITE UNSPECIFIED
239.0 NEOPLASM OF UNSPECIFIED NATURE OF DIGESTIVE SYSTEM
239.1 NEOPLASM OF UNSPECIFIED NATURE OF RESPIRATORY SYSTEM
239.2 NEOPLASM OF UNSPECIFIED NATURE OF BONE SOFT TISSUE AND SKIN
239.3 NEOPLASM OF UNSPECIFIED NATURE OF BREAST
239.4 NEOPLASM OF UNSPECIFIED NATURE OF BLADDER
239.5 NEOPLASM OF UNSPECIFIED NATURE OF OTHER GENITOURINARY ORGANS
239.6 NEOPLASM OF UNSPECIFIED NATURE OF BRAIN
239.7 NEOPLASM OF UNSPECIFIED NATURE OF ENDOCRINE GLANDS AND OTHER PARTS OF NERVOUS SYSTEM
239.81 NEOPLASMS OF UNSPECIFIED NATURE, RETINA AND CHOROID
239.89 NEOPLASMS OF UNSPECIFIED NATURE, OTHER SPECIFIED SITES
239.9 NEOPLASM OF UNSPECIFIED NATURE SITE UNSPECIFIED
285.3 ANTINEOPLASTIC CHEMOTHERAPY INDUCED ANEMIA
J0885 List 1
The diagnosis codes listed below require the use of the EC modifier when submitting claims for J0885. In addition, diagnosis codes marked with an * require a dual diagnosis. The dual diagnosis rules are outlined below.
Dual diagnosis rules:
1.) 403.01, 403.11, 403.91, 404.02, 404.03, 404.12, 404.13, 404.92, 404.93, 585.1, 585.2, 585.3, 585.4, 585.5 or 585.9 AND 285.21 must be billed together.
2.) 042, 070.54, 070.70, V07.8 or 714.0 AND 285.29 or 285.9 must be billed together.
042* HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE
070.54* CHRONIC HEPATITIS C WITHOUT HEPATIC COMA
070.70* UNSPECIFIED VIRAL HEPATITIS C WITHOUT HEPATIC COMA
238.71 ESSENTIAL THROMBOCYTHEMIA
238.72 LOW GRADE MYELODYSPLASTIC SYNDROME LESIONS
238.73 HIGH GRADE MYELODYSPLASTIC SYNDROME LESIONS
238.74 MYELODYSPLASTIC SYNDROME WITH 5Q DELETION
238.75 MYELODYSPLASTIC SYNDROME, UNSPECIFIED
238.76 MYELOFIBROSIS WITH MYELOID METAPLASIA
273.3 MACROGLOBULINEMIA
285.21* ANEMIA IN CHRONIC KIDNEY DISEASE
285.29* ANEMIA OF OTHER CHRONIC DISEASE
285.9* ANEMIA UNSPECIFIED
403.01* HYPERTENSIVE CHRONIC KIDNEY DISEASE, MALIGNANT, WITH CHRONIC KIDNEY DISEASE STAGE V OR END STAGE RENAL DISEASE
403.11* HYPERTENSIVE CHRONIC KIDNEY DISEASE, BENIGN, WITH CHRONIC KIDNEY DISEASE STAGE V OR END STAGE RENAL DISEASE
403.91* HYPERTENSIVE CHRONIC KIDNEY DISEASE, UNSPECIFIED, WITH CHRONIC KIDNEY DISEASE STAGE V OR END STAGE RENAL DISEASE
404.02* HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE, MALIGNANT, WITHOUT HEART FAILURE AND WITH CHRONIC KIDNEY DISEASE STAGE V OR END STAGE RENAL DISEASE
404.03* HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE, MALIGNANT, WITH HEART FAILURE AND WITH CHRONIC KIDNEY DISEASE STAGE V OR END STAGE RENAL DISEASE
404.12* HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE, BENIGN, WITHOUT HEART FAILURE AND WITH CHRONIC KIDNEY DISEASE STAGE V OR END STAGE RENAL DISEASE
404.13* HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE, BENIGN, WITH HEART FAILURE AND CHRONIC KIDNEY DISEASE STAGE V OR END STAGE RENAL DISEASE
404.92* HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE, UNSPECIFIED, WITHOUT HEART FAILURE AND WITH CHRONIC KIDNEY DISEASE STAGE V OR END STAGE RENAL DISEASE
404.93* HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE, UNSPECIFIED, WITH HEART FAILURE AND CHRONIC KIDNEY DISEASE STAGE V OR END STAGE RENAL DISEASE
585.1* CHRONIC KIDNEY DISEASE, STAGE I
585.2* CHRONIC KIDNEY DISEASE, STAGE II (MILD)
585.3* CHRONIC KIDNEY DISEASE, STAGE III (MODERATE)
585.4* CHRONIC KIDNEY DISEASE, STAGE IV (SEVERE)
585.5* CHRONIC KIDNEY DISEASE, STAGE V
585.9* CHRONIC KIDNEY DISEASE, UNSPECIFIED
714.0* RHEUMATOID ARTHRITIS
V07.8* OTHER SPECIFIED PROPHYLACTIC OR TREATMENT MEASURE
J0885 List 2
The following diagnosis codes require the use of the EA modifier when submitting claims for J0885. In addition, ALL diagnosis codes listed below require a dual diagnosis. The dual diagnosis rule is outlined below.
Dual Diagnosis Rule
1.) ALL diagnosis codes listed below for J0885 List 2 require a dual diagnosis in addition to the EA modifier. Diagnosis code 285.3 AND one of the malignancy codes listed below MUST be billed together. All codes listed below except for 285.3 are malignancy codes.
140.0 MALIGNANT NEOPLASM OF UPPER LIP VERMILION BORDER
140.1 MALIGNANT NEOPLASM OF LOWER LIP VERMILION BORDER
140.3 MALIGNANT NEOPLASM OF UPPER LIP INNER ASPECT
140.4 MALIGNANT NEOPLASM OF LOWER LIP INNER ASPECT
140.5 MALIGNANT NEOPLASM OF LIP UNSPECIFIED INNER ASPECT
140.6 MALIGNANT NEOPLASM OF COMMISSURE OF LIP
140.8 MALIGNANT NEOPLASM OF OTHER SITES OF LIP
140.9 MALIGNANT NEOPLASM OF LIP UNSPECIFIED VERMILION BORDER
141.0 MALIGNANT NEOPLASM OF BASE OF TONGUE
141.1 MALIGNANT NEOPLASM OF DORSAL SURFACE OF TONGUE
141.2 MALIGNANT NEOPLASM OF TIP AND LATERAL BORDER OF TONGUE
141.3 MALIGNANT NEOPLASM OF VENTRAL SURFACE OF TONGUE
141.4 MALIGNANT NEOPLASM OF ANTERIOR TWO-THIRDS OF TONGUE PART UNSPECIFIED
141.5 MALIGNANT NEOPLASM OF JUNCTIONAL ZONE OF TONGUE
141.6 MALIGNANT NEOPLASM OF LINGUAL TONSIL
141.8 MALIGNANT NEOPLASM OF OTHER SITES OF TONGUE
141.9 MALIGNANT NEOPLASM OF TONGUE UNSPECIFIED
142.0 MALIGNANT NEOPLASM OF PAROTID GLAND
142.1 MALIGNANT NEOPLASM OF SUBMANDIBULAR GLAND
142.2 MALIGNANT NEOPLASM OF SUBLINGUAL GLAND
142.8 MALIGNANT NEOPLASM OF OTHER MAJOR SALIVARY GLANDS
142.9 MALIGNANT NEOPLASM OF SALIVARY GLAND UNSPECIFIED
143.0 MALIGNANT NEOPLASM OF UPPER GUM
143.1 MALIGNANT NEOPLASM OF LOWER GUM
143.8 MALIGNANT NEOPLASM OF OTHER SITES OF GUM
143.9 MALIGNANT NEOPLASM OF GUM UNSPECIFIED
144.0 MALIGNANT NEOPLASM OF ANTERIOR PORTION OF FLOOR OF MOUTH
144.1 MALIGNANT NEOPLASM OF LATERAL PORTION OF FLOOR OF MOUTH
144.8 MALIGNANT NEOPLASM OF OTHER SITES OF FLOOR OF MOUTH
144.9 MALIGNANT NEOPLASM OF FLOOR OF MOUTH PART UNSPECIFIED
145.0 MALIGNANT NEOPLASM OF CHEEK MUCOSA
145.1 MALIGNANT NEOPLASM OF VESTIBULE OF MOUTH
145.2 MALIGNANT NEOPLASM OF HARD PALATE
145.3 MALIGNANT NEOPLASM OF SOFT PALATE
145.4 MALIGNANT NEOPLASM OF UVULA
145.5 MALIGNANT NEOPLASM OF PALATE UNSPECIFIED
145.6 MALIGNANT NEOPLASM OF RETROMOLAR AREA
145.8 MALIGNANT NEOPLASM OF OTHER SPECIFIED PARTS OF MOUTH
145.9 MALIGNANT NEOPLASM OF MOUTH UNSPECIFIED
146.0 MALIGNANT NEOPLASM OF TONSIL
146.1 MALIGNANT NEOPLASM OF TONSILLAR FOSSA
146.2 MALIGNANT NEOPLASM OF TONSILLAR PILLARS (ANTERIOR) (POSTERIOR)
146.3 MALIGNANT NEOPLASM OF VALLECULA EPIGLOTTICA
146.4 MALIGNANT NEOPLASM OF ANTERIOR ASPECT OF EPIGLOTTIS
146.5 MALIGNANT NEOPLASM OF JUNCTIONAL REGION OF OROPHARYNX
146.6 MALIGNANT NEOPLASM OF LATERAL WALL OF OROPHARYNX
146.7 MALIGNANT NEOPLASM OF POSTERIOR WALL OF OROPHARYNX
146.8 MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF OROPHARYNX
146.9 MALIGNANT NEOPLASM OF OROPHARYNX UNSPECIFIED SITE
147.0 MALIGNANT NEOPLASM OF SUPERIOR WALL OF NASOPHARYNX
147.1 MALIGNANT NEOPLASM OF POSTERIOR WALL OF NASOPHARYNX
147.2 MALIGNANT NEOPLASM OF LATERAL WALL OF NASOPHARYNX
147.3 MALIGNANT NEOPLASM OF ANTERIOR WALL OF NASOPHARYNX
147.8 MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF NASOPHARYNX
147.9 MALIGNANT NEOPLASM OF NASOPHARYNX UNSPECIFIED SITE
148.0 MALIGNANT NEOPLASM OF POSTCRICOID REGION OF HYPOPHARYNX
148.1 MALIGNANT NEOPLASM OF PYRIFORM SINUS
148.2 MALIGNANT NEOPLASM OF ARYEPIGLOTTIC FOLD HYPOPHARYNGEAL ASPECT
148.3 MALIGNANT NEOPLASM OF POSTERIOR HYPOPHARYNGEAL WALL
148.8 MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF HYPOPHARYNX
148.9 MALIGNANT NEOPLASM OF HYPOPHARYNX UNSPECIFIED SITE
149.0 MALIGNANT NEOPLASM OF PHARYNX UNSPECIFIED
149.1 MALIGNANT NEOPLASM OF WALDEYER'S RING
149.8 MALIGNANT NEOPLASM OF OTHER SITES WITHIN THE LIP AND ORAL CAVITY
149.9 MALIGNANT NEOPLASM OF ILL-DEFINED SITES WITHIN THE LIP AND ORAL CAVITY
150.0 MALIGNANT NEOPLASM OF CERVICAL ESOPHAGUS
150.1 MALIGNANT NEOPLASM OF THORACIC ESOPHAGUS
150.2 MALIGNANT NEOPLASM OF ABDOMINAL ESOPHAGUS
150.3 MALIGNANT NEOPLASM OF UPPER THIRD OF ESOPHAGUS
150.4 MALIGNANT NEOPLASM OF MIDDLE THIRD OF ESOPHAGUS
150.5 MALIGNANT NEOPLASM OF LOWER THIRD OF ESOPHAGUS
150.8 MALIGNANT NEOPLASM OF OTHER SPECIFIED PART OF ESOPHAGUS
150.9 MALIGNANT NEOPLASM OF ESOPHAGUS UNSPECIFIED SITE
151.0 MALIGNANT NEOPLASM OF CARDIA
151.1 MALIGNANT NEOPLASM OF PYLORUS
151.2 MALIGNANT NEOPLASM OF PYLORIC ANTRUM
151.3 MALIGNANT NEOPLASM OF FUNDUS OF STOMACH
151.4 MALIGNANT NEOPLASM OF BODY OF STOMACH
151.5 MALIGNANT NEOPLASM OF LESSER CURVATURE OF STOMACH UNSPECIFIED
151.6 MALIGNANT NEOPLASM OF GREATER CURVATURE OF STOMACH UNSPECIFIED
151.8 MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF STOMACH
151.9 MALIGNANT NEOPLASM OF STOMACH UNSPECIFIED SITE
152.0 MALIGNANT NEOPLASM OF DUODENUM
152.1 MALIGNANT NEOPLASM OF JEJUNUM
152.2 MALIGNANT NEOPLASM OF ILEUM
152.3 MALIGNANT NEOPLASM OF MECKEL'S DIVERTICULUM
152.8 MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF SMALL INTESTINE
152.9 MALIGNANT NEOPLASM OF SMALL INTESTINE UNSPECIFIED SITE
153.0 MALIGNANT NEOPLASM OF HEPATIC FLEXURE
153.1 MALIGNANT NEOPLASM OF TRANSVERSE COLON
153.2 MALIGNANT NEOPLASM OF DESCENDING COLON
153.3 MALIGNANT NEOPLASM OF SIGMOID COLON
153.4 MALIGNANT NEOPLASM OF CECUM
153.5 MALIGNANT NEOPLASM OF APPENDIX VERMIFORMIS
153.6 MALIGNANT NEOPLASM OF ASCENDING COLON
153.7 MALIGNANT NEOPLASM OF SPLENIC FLEXURE
153.8 MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF LARGE INTESTINE
153.9 MALIGNANT NEOPLASM OF COLON UNSPECIFIED SITE
154.0 MALIGNANT NEOPLASM OF RECTOSIGMOID JUNCTION
154.1 MALIGNANT NEOPLASM OF RECTUM
154.2 MALIGNANT NEOPLASM OF ANAL CANAL
154.3 MALIGNANT NEOPLASM OF ANUS UNSPECIFIED SITE
154.8 MALIGNANT NEOPLASM OF OTHER SITES OF RECTUM RECTOSIGMOID JUNCTION AND ANUS
155.0 MALIGNANT NEOPLASM OF LIVER PRIMARY
155.1 MALIGNANT NEOPLASM OF INTRAHEPATIC BILE DUCTS
155.2 MALIGNANT NEOPLASM OF LIVER NOT SPECIFIED AS PRIMARY OR SECONDARY
156.0 MALIGNANT NEOPLASM OF GALLBLADDER
156.1 MALIGNANT NEOPLASM OF EXTRAHEPATIC BILE DUCTS
156.2 MALIGNANT NEOPLASM OF AMPULLA OF VATER
156.8 MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF GALLBLADDER AND EXTRAHEPATIC BILE DUCTS
156.9 MALIGNANT NEOPLASM OF BILIARY TRACT PART UNSPECIFIED SITE
157.0 MALIGNANT NEOPLASM OF HEAD OF PANCREAS
157.1 MALIGNANT NEOPLASM OF BODY OF PANCREAS
157.2 MALIGNANT NEOPLASM OF TAIL OF PANCREAS
157.3 MALIGNANT NEOPLASM OF PANCREATIC DUCT
157.4 MALIGNANT NEOPLASM OF ISLETS OF LANGERHANS
157.8 MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF PANCREAS
157.9 MALIGNANT NEOPLASM OF PANCREAS PART UNSPECIFIED
158.0 MALIGNANT NEOPLASM OF RETROPERITONEUM
158.8 MALIGNANT NEOPLASM OF SPECIFIED PARTS OF PERITONEUM
158.9 MALIGNANT NEOPLASM OF PERITONEUM UNSPECIFIED
159.0 MALIGNANT NEOPLASM OF INTESTINAL TRACT PART UNSPECIFIED
159.1 MALIGNANT NEOPLASM OF SPLEEN NOT ELSEWHERE CLASSIFIED
159.8 MALIGNANT NEOPLASM OF OTHER SITES OF DIGESTIVE SYSTEM AND INTRA-ABDOMINAL ORGANS
159.9 MALIGNANT NEOPLASM OF ILL-DEFINED SITES WITHIN THE DIGESTIVE ORGANS AND PERITONEUM
160.0 MALIGNANT NEOPLASM OF NASAL CAVITIES
160.1 MALIGNANT NEOPLASM OF AUDITORY TUBE MIDDLE EAR AND MASTOID AIR CELLS
160.2 MALIGNANT NEOPLASM OF MAXILLARY SINUS
160.3 MALIGNANT NEOPLASM OF ETHMOIDAL SINUS
160.4 MALIGNANT NEOPLASM OF FRONTAL SINUS
160.5 MALIGNANT NEOPLASM OF SPHENOIDAL SINUS
160.8 MALIGNANT NEOPLASM OF OTHER ACCESSORY SINUSES
160.9 MALIGNANT NEOPLASM OF ACCESSORY SINUS UNSPECIFIED
161.0 MALIGNANT NEOPLASM OF GLOTTIS
161.1 MALIGNANT NEOPLASM OF SUPRAGLOTTIS
161.2 MALIGNANT NEOPLASM OF SUBGLOTTIS
161.3 MALIGNANT NEOPLASM OF LARYNGEAL CARTILAGES
161.8 MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF LARYNX
161.9 MALIGNANT NEOPLASM OF LARYNX UNSPECIFIED
162.0 MALIGNANT NEOPLASM OF TRACHEA
162.2 MALIGNANT NEOPLASM OF MAIN BRONCHUS
162.3 MALIGNANT NEOPLASM OF UPPER LOBE BRONCHUS OR LUNG
162.4 MALIGNANT NEOPLASM OF MIDDLE LOBE BRONCHUS OR LUNG
162.5 MALIGNANT NEOPLASM OF LOWER LOBE BRONCHUS OR LUNG
162.8 MALIGNANT NEOPLASM OF OTHER PARTS OF BRONCHUS OR LUNG
162.9 MALIGNANT NEOPLASM OF BRONCHUS AND LUNG UNSPECIFIED
163.0 MALIGNANT NEOPLASM OF PARIETAL PLEURA
163.1 MALIGNANT NEOPLASM OF VISCERAL PLEURA
163.8 MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF PLEURA
163.9 MALIGNANT NEOPLASM OF PLEURA UNSPECIFIED
164.0 MALIGNANT NEOPLASM OF THYMUS
164.1 MALIGNANT NEOPLASM OF HEART
164.2 MALIGNANT NEOPLASM OF ANTERIOR MEDIASTINUM
164.3 MALIGNANT NEOPLASM OF POSTERIOR MEDIASTINUM
164.8 MALIGNANT NEOPLASM OF OTHER PARTS OF MEDIASTINUM
164.9 MALIGNANT NEOPLASM OF MEDIASTINUM PART UNSPECIFIED
165.0 MALIGNANT NEOPLASM OF UPPER RESPIRATORY TRACT PART UNSPECIFIED
165.8 MALIGNANT NEOPLASM OF OTHER SITES WITHIN THE RESPIRATORY SYSTEM AND INTRATHORACIC ORGANS
165.9 MALIGNANT NEOPLASM OF ILL-DEFINED SITES WITHIN THE RESPIRATORY SYSTEM
170.0 MALIGNANT NEOPLASM OF BONES OF SKULL AND FACE EXCEPT MANDIBLE
170.1 MALIGNANT NEOPLASM OF MANDIBLE
170.2 MALIGNANT NEOPLASM OF VERTEBRAL COLUMN EXCLUDING SACRUM AND COCCYX
170.3 MALIGNANT NEOPLASM OF RIBS STERNUM AND CLAVICLE
170.4 MALIGNANT NEOPLASM OF SCAPULA AND LONG BONES OF UPPER LIMB
170.5 MALIGNANT NEOPLASM OF SHORT BONES OF UPPER LIMB
170.6 MALIGNANT NEOPLASM OF PELVIC BONES SACRUM AND COCCYX
170.7 MALIGNANT NEOPLASM OF LONG BONES OF LOWER LIMB
170.8 MALIGNANT NEOPLASM OF SHORT BONES OF LOWER LIMB
170.9 MALIGNANT NEOPLASM OF BONE AND ARTICULAR CARTILAGE SITE UNSPECIFIED
171.0 MALIGNANT NEOPLASM OF CONNECTIVE AND OTHER SOFT TISSUE OF HEAD FACE AND NECK
171.2 MALIGNANT NEOPLASM OF CONNECTIVE AND OTHER SOFT TISSUE OF UPPER LIMB INCLUDING SHOULDER
171.3 MALIGNANT NEOPLASM OF CONNECTIVE AND OTHER SOFT TISSUE OF LOWER LIMB INCLUDING HIP
171.4 MALIGNANT NEOPLASM OF CONNECTIVE AND OTHER SOFT TISSUE OF THORAX
171.5 MALIGNANT NEOPLASM OF CONNECTIVE AND OTHER SOFT TISSUE OF ABDOMEN
171.6 MALIGNANT NEOPLASM OF CONNECTIVE AND OTHER SOFT TISSUE OF PELVIS
171.7 MALIGNANT NEOPLASM OF CONNECTIVE AND OTHER SOFT TISSUE OF TRUNK UNSPECIFIED
171.8 MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF CONNECTIVE AND OTHER SOFT TISSUE
171.9 MALIGNANT NEOPLASM OF CONNECTIVE AND OTHER SOFT TISSUE SITE UNSPECIFIED
172.0 MALIGNANT MELANOMA OF SKIN OF LIP
172.1 MALIGNANT MELANOMA OF SKIN OF EYELID INCLUDING CANTHUS
172.2 MALIGNANT MELANOMA OF SKIN OF EAR AND EXTERNAL AUDITORY CANAL
172.3 MALIGNANT MELANOMA OF SKIN OF OTHER AND UNSPECIFIED PARTS OF FACE
172.4 MALIGNANT MELANOMA OF SKIN OF SCALP AND NECK
172.5 MALIGNANT MELANOMA OF SKIN OF TRUNK EXCEPT SCROTUM
172.6 MALIGNANT MELANOMA OF SKIN OF UPPER LIMB INCLUDING SHOULDER
172.7 MALIGNANT MELANOMA OF SKIN OF LOWER LIMB INCLUDING HIP
172.8 MALIGNANT MELANOMA OF OTHER SPECIFIED SITES OF SKIN
172.9 MELANOMA OF SKIN SITE UNSPECIFIED
173.00 UNSPECIFIED MALIGNANT NEOPLASM OF SKIN OF LIP
173.01 BASAL CELL CARCINOMA OF SKIN OF LIP
173.02 SQUAMOUS CELL CARCINOMA OF SKIN OF LIP
173.09 OTHER SPECIFIED MALIGNANT NEOPLASM OF SKIN OF LIP
173.10 UNSPECIFIED MALIGNANT NEOPLASM OF EYELID, INCLUDING CANTHUS
173.11 BASAL CELL CARCINOMA OF EYELID, INCLUDING CANTHUS
173.12 SQUAMOUS CELL CARCINOMA OF EYELID, INCLUDING CANTHUS
173.19 OTHER SPECIFIED MALIGNANT NEOPLASM OF EYELID, INCLUDING CANTHUS
173.20 UNSPECIFIED MALIGNANT NEOPLASM OF SKIN OF EAR AND EXTERNAL AUDITORY CANAL
173.21 BASAL CELL CARCINOMA OF SKIN OF EAR AND EXTERNAL AUDITORY CANAL
173.22 SQUAMOUS CELL CARCINOMA OF SKIN OF EAR AND EXTERNAL AUDITORY CANAL
173.29 OTHER SPECIFIED MALIGNANT NEOPLASM OF SKIN OF EAR AND EXTERNAL AUDITORY CANAL
173.30 UNSPECIFIED MALIGNANT NEOPLASM OF SKIN OF OTHER AND UNSPECIFIED PARTS OF FACE
173.31 BASAL CELL CARCINOMA OF SKIN OF OTHER AND UNSPECIFIED PARTS OF FACE
173.32 SQUAMOUS CELL CARCINOMA OF SKIN OF OTHER AND UNSPECIFIED PARTS OF FACE
173.39 OTHER SPECIFIED MALIGNANT NEOPLASM OF SKIN OF OTHER AND UNSPECIFIED PARTS OF FACE
173.40 UNSPECIFIED MALIGNANT NEOPLASM OF SCALP AND SKIN OF NECK
173.41 BASAL CELL CARCINOMA OF SCALP AND SKIN OF NECK
173.42 SQUAMOUS CELL CARCINOMA OF SCALP AND SKIN OF NECK
173.49 OTHER SPECIFIED MALIGNANT NEOPLASM OF SCALP AND SKIN OF NECK
173.50 UNSPECIFIED MALIGNANT NEOPLASM OF SKIN OF TRUNK, EXCEPT SCROTUM
173.51 BASAL CELL CARCINOMA OF SKIN OF TRUNK, EXCEPT SCROTUM
173.52 SQUAMOUS CELL CARCINOMA OF SKIN OF TRUNK, EXCEPT SCROTUM
173.59 OTHER SPECIFIED MALIGNANT NEOPLASM OF SKIN OF TRUNK, EXCEPT SCROTUM
173.60 UNSPECIFIED MALIGNANT NEOPLASM OF SKIN OF UPPER LIMB, INCLUDING SHOULDER
173.61 BASAL CELL CARCINOMA OF SKIN OF UPPER LIMB, INCLUDING SHOULDER
173.62 SQUAMOUS CELL CARCINOMA OF SKIN OF UPPER LIMB, INCLUDING SHOULDER
173.69 OTHER SPECIFIED MALIGNANT NEOPLASM OF SKIN OF UPPER LIMB, INCLUDING SHOULDER
173.70 UNSPECIFIED MALIGNANT NEOPLASM OF SKIN OF LOWER LIMB, INCLUDING HIP
173.71 BASAL CELL CARCINOMA OF SKIN OF LOWER LIMB, INCLUDING HIP
173.72 SQUAMOUS CELL CARCINOMA OF SKIN OF LOWER LIMB, INCLUDING HIP
173.79 OTHER SPECIFIED MALIGNANT NEOPLASM OF SKIN OF LOWER LIMB, INCLUDING HIP
173.80 UNSPECIFIED MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF SKIN
173.81 BASAL CELL CARCINOMA OF OTHER SPECIFIED SITES OF SKIN
173.82 SQUAMOUS CELL CARCINOMA OF OTHER SPECIFIED SITES OF SKIN
173.89 OTHER SPECIFIED MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF SKIN
173.90 UNSPECIFIED MALIGNANT NEOPLASM OF SKIN, SITE UNSPECIFIED
173.91 BASAL CELL CARCINOMA OF SKIN, SITE UNSPECIFIED
173.92 SQUAMOUS CELL CARCINOMA OF SKIN, SITE UNSPECIFIED
173.99 OTHER SPECIFIED MALIGNANT NEOPLASM OF SKIN, SITE UNSPECIFIED
174.0 MALIGNANT NEOPLASM OF NIPPLE AND AREOLA OF FEMALE BREAST
174.1 MALIGNANT NEOPLASM OF CENTRAL PORTION OF FEMALE BREAST
174.2 MALIGNANT NEOPLASM OF UPPER-INNER QUADRANT OF FEMALE BREAST
174.3 MALIGNANT NEOPLASM OF LOWER-INNER QUADRANT OF FEMALE BREAST
174.4 MALIGNANT NEOPLASM OF UPPER-OUTER QUADRANT OF FEMALE BREAST
174.5 MALIGNANT NEOPLASM OF LOWER-OUTER QUADRANT OF FEMALE BREAST
174.6 MALIGNANT NEOPLASM OF AXILLARY TAIL OF FEMALE BREAST
174.8 MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF FEMALE BREAST
174.9 MALIGNANT NEOPLASM OF BREAST (FEMALE) UNSPECIFIED SITE
175.0 MALIGNANT NEOPLASM OF NIPPLE AND AREOLA OF MALE BREAST
175.9 MALIGNANT NEOPLASM OF OTHER AND UNSPECIFIED SITES OF MALE BREAST
176.0 KAPOSI'S SARCOMA SKIN
176.1 KAPOSI'S SARCOMA SOFT TISSUE
176.2 KAPOSI'S SARCOMA PALATE
176.3 KAPOSI'S SARCOMA GASTROINTESTINAL SITES
176.4 KAPOSI'S SARCOMA LUNG
176.5 KAPOSI'S SARCOMA LYMPH NODES
176.8 KAPOSI'S SARCOMA OTHER SPECIFIED SITES
176.9 KAPOSI'S SARCOMA UNSPECIFIED SITE
179 MALIGNANT NEOPLASM OF UTERUS-PART UNS
180.0 MALIGNANT NEOPLASM OF ENDOCERVIX
180.1 MALIGNANT NEOPLASM OF EXOCERVIX
180.8 MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF CERVIX
180.9 MALIGNANT NEOPLASM OF CERVIX UTERI UNSPECIFIED SITE
181 MALIGNANT NEOPLASM OF PLACENTA
182.0 MALIGNANT NEOPLASM OF CORPUS UTERI EXCEPT ISTHMUS
182.1 MALIGNANT NEOPLASM OF ISTHMUS
182.8 MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF BODY OF UTERUS
183.0 MALIGNANT NEOPLASM OF OVARY
183.2 MALIGNANT NEOPLASM OF FALLOPIAN TUBE
183.3 MALIGNANT NEOPLASM OF BROAD LIGAMENT OF UTERUS
183.4 MALIGNANT NEOPLASM OF PARAMETRIUM
183.5 MALIGNANT NEOPLASM OF ROUND LIGAMENT OF UTERUS
183.8 MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF UTERINE ADNEXA
183.9 MALIGNANT NEOPLASM OF UTERINE ADNEXA UNSPECIFIED SITE
184.0 MALIGNANT NEOPLASM OF VAGINA
184.1 MALIGNANT NEOPLASM OF LABIA MAJORA
184.2 MALIGNANT NEOPLASM OF LABIA MINORA
184.3 MALIGNANT NEOPLASM OF CLITORIS
184.4 MALIGNANT NEOPLASM OF VULVA UNSPECIFIED SITE
184.8 MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF FEMALE GENITAL ORGANS
184.9 MALIGNANT NEOPLASM OF FEMALE GENITAL ORGAN SITE UNSPECIFIED
185 MALIGNANT NEOPLASM OF PROSTATE
186.0 MALIGNANT NEOPLASM OF UNDESCENDED TESTIS
186.9 MALIGNANT NEOPLASM OF OTHER AND UNSPECIFIED TESTIS
187.1 MALIGNANT NEOPLASM OF PREPUCE
187.2 MALIGNANT NEOPLASM OF GLANS PENIS
187.3 MALIGNANT NEOPLASM OF BODY OF PENIS
187.4 MALIGNANT NEOPLASM OF PENIS PART UNSPECIFIED
187.5 MALIGNANT NEOPLASM OF EPIDIDYMIS
187.6 MALIGNANT NEOPLASM OF SPERMATIC CORD
187.7 MALIGNANT NEOPLASM OF SCROTUM
187.8 MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF MALE GENITAL ORGANS
187.9 MALIGNANT NEOPLASM OF MALE GENITAL ORGAN SITE UNSPECIFIED
188.0 MALIGNANT NEOPLASM OF TRIGONE OF URINARY BLADDER
188.1 MALIGNANT NEOPLASM OF DOME OF URINARY BLADDER
188.2 MALIGNANT NEOPLASM OF LATERAL WALL OF URINARY BLADDER
188.3 MALIGNANT NEOPLASM OF ANTERIOR WALL OF URINARY BLADDER
188.4 MALIGNANT NEOPLASM OF POSTERIOR WALL OF URINARY BLADDER
188.5 MALIGNANT NEOPLASM OF BLADDER NECK
188.6 MALIGNANT NEOPLASM OF URETERIC ORIFICE
188.7 MALIGNANT NEOPLASM OF URACHUS
188.8 MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF BLADDER
188.9 MALIGNANT NEOPLASM OF BLADDER PART UNSPECIFIED
189.0 MALIGNANT NEOPLASM OF KIDNEY EXCEPT PELVIS
189.1 MALIGNANT NEOPLASM OF RENAL PELVIS
189.2 MALIGNANT NEOPLASM OF URETER
189.3 MALIGNANT NEOPLASM OF URETHRA
189.4 MALIGNANT NEOPLASM OF PARAURETHRAL GLANDS
189.8 MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF URINARY ORGANS
189.9 MALIGNANT NEOPLASM OF URINARY ORGAN SITE UNSPECIFIED
190.0 MALIGNANT NEOPLASM OF EYEBALL EXCEPT CONJUNCTIVA CORNEA RETINA AND CHOROID
190.1 MALIGNANT NEOPLASM OF ORBIT
190.2 MALIGNANT NEOPLASM OF LACRIMAL GLAND
190.3 MALIGNANT NEOPLASM OF CONJUNCTIVA
190.4 MALIGNANT NEOPLASM OF CORNEA
190.5 MALIGNANT NEOPLASM OF RETINA
190.6 MALIGNANT NEOPLASM OF CHOROID
190.7 MALIGNANT NEOPLASM OF LACRIMAL DUCT
190.8 MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF EYE
190.9 MALIGNANT NEOPLASM OF EYE PART UNSPECIFIED
191.0 MALIGNANT NEOPLASM OF CEREBRUM EXCEPT LOBES AND VENTRICLES
191.1 MALIGNANT NEOPLASM OF FRONTAL LOBE
191.2 MALIGNANT NEOPLASM OF TEMPORAL LOBE
191.3 MALIGNANT NEOPLASM OF PARIETAL LOBE
191.4 MALIGNANT NEOPLASM OF OCCIPITAL LOBE
191.5 MALIGNANT NEOPLASM OF VENTRICLES
191.6 MALIGNANT NEOPLASM OF CEREBELLUM NOS
191.7 MALIGNANT NEOPLASM OF BRAIN STEM
191.8 MALIGNANT NEOPLASM OF OTHER PARTS OF BRAIN
191.9 MALIGNANT NEOPLASM OF BRAIN UNSPECIFIED SITE
192.0 MALIGNANT NEOPLASM OF CRANIAL NERVES
192.1 MALIGNANT NEOPLASM OF CEREBRAL MENINGES
192.2 MALIGNANT NEOPLASM OF SPINAL CORD
192.3 MALIGNANT NEOPLASM OF SPINAL MENINGES
192.8 MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF NERVOUS SYSTEM
192.9 MALIGNANT NEOPLASM OF NERVOUS SYSTEM PART UNSPECIFIED
193 MALIGNANT NEOPLASM OF THYROID GLAND
194.0 MALIGNANT NEOPLASM OF ADRENAL GLAND
194.1 MALIGNANT NEOPLASM OF PARATHYROID GLAND
194.3 MALIGNANT NEOPLASM OF PITUITARY GLAND AND CRANIOPHARYNGEAL DUCT
194.4 MALIGNANT NEOPLASM OF PINEAL GLAND
194.5 MALIGNANT NEOPLASM OF CAROTID BODY
194.6 MALIGNANT NEOPLASM OF AORTIC BODY AND OTHER PARAGANGLIA
194.8 MALIGNANT NEOPLASM OF OTHER ENDOCRINE GLANDS AND RELATED STRUCTURES
194.9 MALIGNANT NEOPLASM OF ENDOCRINE GLAND SITE UNSPECIFIED
195.0 MALIGNANT NEOPLASM OF HEAD FACE AND NECK
195.1 MALIGNANT NEOPLASM OF THORAX
195.2 MALIGNANT NEOPLASM OF ABDOMEN
195.3 MALIGNANT NEOPLASM OF PELVIS
195.4 MALIGNANT NEOPLASM OF UPPER LIMB
195.5 MALIGNANT NEOPLASM OF LOWER LIMB
195.8 MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES
196.0 SECONDARY AND UNSPECIFIED MALIGNANT NEOPLASM OF LYMPH NODES OF HEAD FACE AND NECK
196.1 SECONDARY AND UNSPECIFIED MALIGNANT NEOPLASM OF INTRATHORACIC LYMPH NODES
196.2 SECONDARY AND UNSPECIFIED MALIGNANT NEOPLASM OF INTRA-ABDOMINAL LYMPH NODES
196.3 SECONDARY AND UNSPECIFIED MALIGNANT NEOPLASM OF LYMPH NODES OF AXILLA AND UPPER LIMB
196.5 SECONDARY AND UNSPECIFIED MALIGNANT NEOPLASM OF LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
196.6 SECONDARY AND UNSPECIFIED MALIGNANT NEOPLASM OF INTRAPELVIC LYMPH NODES
196.8 SECONDARY AND UNSPECIFIED MALIGNANT NEOPLASM OF LYMPH NODES OF MULTIPLE SITES
196.9 SECONDARY AND UNSPECIFIED MALIGNANT NEOPLASM OF LYMPH NODES SITE UNSPECIFIED
197.0 SECONDARY MALIGNANT NEOPLASM OF LUNG
197.1 SECONDARY MALIGNANT NEOPLASM OF MEDIASTINUM
197.2 SECONDARY MALIGNANT NEOPLASM OF PLEURA
197.3 SECONDARY MALIGNANT NEOPLASM OF OTHER RESPIRATORY ORGANS
197.4 SECONDARY MALIGNANT NEOPLASM OF SMALL INTESTINE INCLUDING DUODENUM
197.5 SECONDARY MALIGNANT NEOPLASM OF LARGE INTESTINE AND RECTUM
197.6 SECONDARY MALIGNANT NEOPLASM OF RETROPERITONEUM AND PERITONEUM
197.7 MALIGNANT NEOPLASM OF LIVER SECONDARY
197.8 SECONDARY MALIGNANT NEOPLASM OF OTHER DIGESTIVE ORGANS AND SPLEEN
198.0 SECONDARY MALIGNANT NEOPLASM OF KIDNEY
198.1 SECONDARY MALIGNANT NEOPLASM OF OTHER URINARY ORGANS
198.2 SECONDARY MALIGNANT NEOPLASM OF SKIN
198.3 SECONDARY MALIGNANT NEOPLASM OF BRAIN AND SPINAL CORD
198.4 SECONDARY MALIGNANT NEOPLASM OF OTHER PARTS OF NERVOUS SYSTEM
198.5 SECONDARY MALIGNANT NEOPLASM OF BONE AND BONE MARROW
198.6 SECONDARY MALIGNANT NEOPLASM OF OVARY
198.7 SECONDARY MALIGNANT NEOPLASM OF ADRENAL GLAND
198.81 SECONDARY MALIGNANT NEOPLASM OF BREAST
198.82 SECONDARY MALIGNANT NEOPLASM OF GENITAL ORGANS
198.89 SECONDARY MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES
199.0 DISSEMINATED MALIGNANT NEOPLASM
199.1 OTHER MALIGNANT NEOPLASM OF UNSPECIFIED SITE
199.2 MALIGNANT NEOPLASM ASSOCIATED WITH TRANSPLANT ORGAN
200.00 RETICULOSARCOMA UNSPECIFIED SITE
200.01 RETICULOSARCOMA INVOLVING LYMPH NODES OF HEAD FACE AND NECK
200.02 RETICULOSARCOMA INVOLVING INTRATHORACIC LYMPH NODES
200.03 RETICULOSARCOMA INVOLVING INTRA-ABDOMINAL LYMPH NODES
200.04 RETICULOSARCOMA INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB
200.05 RETICULOSARCOMA INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
200.06 RETICULOSARCOMA INVOLVING INTRAPELVIC LYMPH NODES
200.07 RETICULOSARCOMA INVOLVING SPLEEN
200.08 RETICULOSARCOMA INVOLVING LYMPH NODES OF MULTIPLE SITES
200.10 LYMPHOSARCOMA UNSPECIFIED SITE
200.11 LYMPHOSARCOMA INVOLVING LYMPH NODES OF HEAD FACE AND NECK
200.12 LYMPHOSARCOMA INVOLVING INTRATHORACIC LYMPH NODES
200.13 LYMPHOSARCOMA INVOLVING INTRA-ABDOMINAL LYMPH NODES
200.14 LYMPHOSARCOMA INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB
200.15 LYMPHOSARCOMA INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
200.16 LYMPHOSARCOMA INVOLVING INTRAPELVIC LYMPH NODES
200.17 LYMPHOSARCOMA INVOLVING SPLEEN
200.18 LYMPHOSARCOMA INVOLVING LYMPH NODES OF MULTIPLE SITES
200.20 BURKITT'S TUMOR OR LYMPHOMA UNSPECIFIED SITE
200.21 BURKITT'S TUMOR OR LYMPHOMA INVOLVING LYMPH NODES OF HEAD FACE AND NECK
200.22 BURKITT'S TUMOR OR LYMPHOMA INVOLVING INTRATHORACIC LYMPH NODES
200.23 BURKITT'S TUMOR OR LYMPHOMA INVOLVING INTRA-ABDOMINAL LYMPH NODES
200.24 BURKITT'S TUMOR OR LYMPHOMA INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB
200.25 BURKITT'S TUMOR OR LYMPHOMA INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
200.26 BURKITT'S TUMOR OR LYMPHOMA INVOLVING INTRAPELVIC LYMPH NODES
200.27 BURKITT'S TUMOR OR LYMPHOMA INVOLVING SPLEEN
200.28 BURKITT'S TUMOR OR LYMPHOMA INVOLVING LYMPH NODES OF MULTIPLE SITES
200.30 MARGINAL ZONE LYMPHOMA, UNSPECIFIED SITE, EXTRANODAL AND SOLID ORGAN SITES
200.31 MARGINAL ZONE LYMPHOMA,LYMPH NODES OF HEAD, FACE, AND NECK
200.32 MARGINAL ZONE LYMPHOMA,INTRATHORACIC LYMPH NODES
200.33 MARGINAL ZONE LYMPHOMA, INTRAABDOMINAL LYMPH NODES
200.34 MARGINAL ZONE LYMPHOMA, LYMPH NODES OF AXILLA AND UPPER LIMB
200.35 MARGINAL ZONE LYMPHOMA, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
200.36 MARGINAL ZONE LYMPHOMA, INTRAPELVIC LYMPH NODES
200.37 MARGINAL ZONE LYMPHOMA, SPLEEN
200.38 MARGINAL ZONE LYMPHOMA, LYMPH NODES OF MULTIPLE SITES
200.40 MANTLE CELL LYMPHOMA, UNSPECIFIED SITE, EXTRANODAL AND SOLID ORGAN SITES
200.41 MANTLE CELL LYMPHOMA, LYMPH NODES OF HEAD, FACE, AND NECK
200.42 MANTLE CELL LYMPHOMA, INTRATHORACIC LYMPH NODES
200.43 MANTLE CELL LYMPHOMA, INTRA-ABDOMINAL LYMPH NODES
200.44 MANTLE CELL LYMPHOMA, LYMPH NODES OF AXILLA AND UPPER LIMB
200.45 MANTLE CELL LYMPHOMA, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
200.46 MANTLE CELL LYMPHOMA, INTRAPELVIC LYMPH NODES
200.47 MANTLE CELL LYMPHOMA, SPLEEN
200.48 MANTLE CELL LYMPHOMA, LYMPH NODES OF MULTIPLE SITES
200.50 PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA, UNSPECIFIED SITE, EXTRANODAL AND SOLID ORGAN SITES
200.51 PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA, LYMPH NODES OF HEAD, FACE, AND NECK
200.52 PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA, INTRATHORACIC LYMPH NODES
200.53 PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA, INTRA-ABDOMINAL LYMPH NODES
200.54 PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA, LYMPH NODES OF AXILLA AND UPPER LIMB
200.55 PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
200.56 PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA, INTRAPELVIC LYMPH NODES
200.57 PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA, SPLEEN
200.58 PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA, LYMPH NODES OF MULTIPLE SITES
200.60 ANAPLASTIC LARGE CELL LYMPHOMA, UNSPECIFIED SITE, EXTRANODAL AND SOLID ORGAN SITES
200.61 ANAPLASTIC LARGE CELL LYMPHOMA, LYMPH NODES OF HEAD, FACE, AND NECK
200.62 ANAPLASTIC LARGE CELL LYMPHOMA, INTRATHORACIC LYMPH NODES
200.63 ANAPLASTIC LARGE CELL LYMPHOMA, INTRA-ABDOMINAL LYMPH NODES
200.64 ANAPLASTIC LARGE CELL LYMPHOMA, LYMPH NODES OF AXILLA AND UPPER LIMB
200.65 ANAPLASTIC LARGE CELL LYMPHOMA, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
200.66 ANAPLASTIC LARGE CELL LYMPHOMA, INTRAPELVIC LYMPH NODES
200.67 ANAPLASTIC LARGE CELL LYMPHOMA, SPLEEN
200.68 ANAPLASTIC LARGE CELL LYMPHOMA, LYMPH NODES OF MULTIPLE SITES
200.70 LARGE CELL LYMPHOMA, UNSPECIFIED SITE, EXTRANODAL AND SOLID ORGAN SITES
200.71 LARGE CELL LYMPHOMA, LYMPH NODES OF HEAD, FACE, AND NECK
200.72 LARGE CELL LYMPHOMA, INTRATHORACIC LYMPH NODES
200.73 LARGE CELL LYMPHOMA, INTRA-ABDOMINAL LYMPH NODES
200.74 LARGE CELL LYMPHOMA, LYMPH NODES OF AXILLA AND UPPER LIMB
200.75 LARGE CELL LYMPHOMA, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
200.76 LARGE CELL LYMPHOMA, INTRAPELVIC LYMPH NODES
200.77 LARGE CELL LYMPHOMA, SPLEEN
200.78 LARGE CELL LYMPHOMA, LYMPH NODES OF MULTIPLE SITES
200.80 OTHER NAMED VARIANTS OF LYMPHOSARCOMA AND RETICULOSARCOMA UNSPECIFIED SITE
200.81 OTHER NAMED VARIANTS OF LYMPHOSARCOMA AND RETICULOSARCOMA INVOLVING LYMPH NODES OF HEAD FACE AND NECK
200.82 OTHER NAMED VARIANTS OF LYMPHOSARCOMA AND RETICULOSARCOMA INVOLVING INTRATHORACIC LYMPH NODES
200.83 OTHER NAMED VARIANTS OF LYMPHOSARCOMA AND RETICULOSARCOMA INVOLVING INTRA-ABDOMINAL LYMPH NODES
200.84 OTHER NAMED VARIANTS OF LYMPHOSARCOMA AND RETICULOSARCOMA INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB
200.85 OTHER NAMED VARIANTS OF LYMPHOSARCOMA AND RETICULOSARCOMA INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
200.86 OTHER NAMED VARIANTS OF LYMPHOSARCOMA AND RETICULOSARCOMA INVOLVING INTRAPELVIC LYMPH NODES
200.87 OTHER NAMED VARIANTS OF LYMPHOSARCOMA AND RETICULOSARCOMA INVOLVING SPLEEN
200.88 OTHER NAMED VARIANTS OF LYMPHOSARCOMA AND RETICULOSARCOMA INVOLVING LYMPH NODES OF MULTIPLE SITES
201.00 HODGKIN'S PARAGRANULOMA UNSPECIFIED SITE
201.01 HODGKIN'S PARAGRANULOMA INVOLVING LYMPH NODES OF HEAD FACE AND NECK
201.02 HODGKIN'S PARAGRANULOMA INVOLVING INTRATHORACIC LYMPH NODES
201.03 HODGKIN'S PARAGRANULOMA INVOLVING INTRA-ABDOMINAL LYMPH NODES
201.04 HODGKIN'S PARAGRANULOMA INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB
201.05 HODGKIN'S PARAGRANULOMA INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
201.06 HODGKIN'S PARAGRANULOMA INVOLVING INTRAPELVIC LYMPH NODES
201.07 HODGKIN'S PARAGRANULOMA INVOLVING SPLEEN
201.08 HODGKIN'S PARAGRANULOMA INVOLVING LYMPH NODES OF MULTIPLE SITES
201.10 HODGKIN'S GRANULOMA UNSPECIFIED SITE
201.11 HODGKIN'S GRANULOMA INVOLVING LYMPH NODES OF HEAD FACE AND NECK
201.12 HODGKIN'S GRANULOMA INVOLVING INTRATHORACIC LYMPH NODES
201.13 HODGKIN'S GRANULOMA INVOLVING INTRA-ABDOMINAL LYMPH NODES
201.14 HODGKIN'S GRANULOMA INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB
201.15 HODGKIN'S GRANULOMA INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
201.16 HODGKIN'S GRANULOMA INVOLVING INTRAPELVIC LYMPH NODES
201.17 HODGKIN'S GRANULOMA INVOLVING SPLEEN
201.18 HODGKIN'S GRANULOMA INVOLVING LYMPH NODES OF MULTIPLE SITES
201.20 HODGKIN'S SARCOMA UNSPECIFIED SITE
201.21 HODGKIN'S SARCOMA INVOLVING LYMPH NODES OF HEAD FACE AND NECK
201.22 HODGKIN'S SARCOMA INVOLVING INTRATHORACIC LYMPH NODES
201.23 HODGKIN'S SARCOMA INVOLVING INTRA-ABDOMINAL LYMPH NODES
201.24 HODGKIN'S SARCOMA INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB
201.25 HODGKIN'S SARCOMA INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
201.26 HODGKIN'S SARCOMA INVOLVING INTRAPELVIC LYMPH NODES
201.27 HODGKIN'S SARCOMA INVOLVING SPLEEN
201.28 HODGKIN'S SARCOMA INVOLVING LYMPH NODES OF MULTIPLE SITES
201.40 HODGKIN'S DISEASE LYMPHOCYTIC-HISTIOCYTIC PREDOMINANCE UNSPECIFIED SITE
201.41 HODGKIN'S DISEASE LYMPHOCYTIC-HISTIOCYTIC PREDOMINANCE INVOLVING LYMPH NODES OF HEAD FACE AND NECK
201.42 HODGKIN'S DISEASE LYMPHOCYTIC-HISTIOCYTIC PREDOMINANCE INVOLVING INTRATHORACIC LYMPH NODES
201.43 HODGKIN'S DISEASE LYMPHOCYTIC-HISTIOCYTIC PREDOMINANCE INVOLVING INTRA-ABDOMINAL LYMPH NODES
201.44 HODGKIN'S DISEASE LYMPHOCYTIC-HISTIOCYTIC PREDOMINANCE INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB
201.45 HODGKIN'S DISEASE LYMPHOCYTIC-HISTIOCYTIC PREDOMINANCE INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
201.46 HODGKIN'S DISEASE LYMPHOCYTIC-HISTIOCYTIC PREDOMINANCE INVOLVING INTRAPELVIC LYMPH NODES
201.47 HODGKIN'S DISEASE LYMPHOCYTIC-HISTIOCYTIC PREDOMINANCE INVOLVING SPLEEN
201.48 HODGKIN'S DISEASE LYMPHOCYTIC-HISTIOCYTIC PREDOMINANCE INVOLVING LYMPH NODES OF MULTIPLE SITES
201.50 HODGKIN'S DISEASE NODULAR SCLEROSIS UNSPECIFIED SITE
201.51 HODGKIN'S DISEASE NODULAR SCLEROSIS INVOLVING LYMPH NODES OF HEAD FACE AND NECK
201.52 HODGKIN'S DISEASE NODULAR SCLEROSIS INVOLVING INTRATHORACIC LYMPH NODES
201.53 HODGKIN'S DISEASE NODULAR SCLEROSIS INVOLVING INTRA-ABDOMINAL LYMPH NODES
201.54 HODGKIN'S DISEASE NODULAR SCLEROSIS INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB
201.55 HODGKIN'S DISEASE NODULAR SCLEROSIS INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
201.56 HODGKIN'S DISEASE NODULAR SCLEROSIS INVOLVING INTRAPELVIC LYMPH NODES
201.57 HODGKIN'S DISEASE NODULAR SCLEROSIS INVOLVING SPLEEN
201.58 HODGKIN'S DISEASE NODULAR SCLEROSIS INVOLVING LYMPH NODES OF MULTIPLE SITES
201.60 HODGKIN'S DISEASE MIXED CELLULARITY UNSPECIFIED SITE
201.61 HODGKIN'S DISEASE MIXED CELLULARITY INVOLVING LYMPH NODES OF HEAD FACE AND NECK
201.62 HODGKIN'S DISEASE MIXED CELLULARITY INVOLVING INTRATHORACIC LYMPH NODES
201.63 HODGKIN'S DISEASE MIXED CELLULARITY INVOLVING INTRA-ABDOMINAL LYMPH NODES
201.64 HODGKIN'S DISEASE MIXED CELLULARITY INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB
201.65 HODGKIN'S DISEASE MIXED CELLULARITY INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
201.66 HODGKIN'S DISEASE MIXED CELLULARITY INVOLVING INTRAPELVIC LYMPH NODES
201.67 HODGKIN'S DISEASE MIXED CELLULARITY INVOLVING SPLEEN
201.68 HODGKIN'S DISEASE MIXED CELLULARITY INVOLVING LYMPH NODES OF MULTIPLE SITES
201.70 HODGKIN'S DISEASE LYMPHOCYTIC DEPLETION UNSPECIFIED SITE
201.71 HODGKIN'S DISEASE LYMPHOCYTIC DEPLETION INVOLVING LYMPH NODES OF HEAD FACE AND NECK
201.72 HODGKIN'S DISEASE LYMPHOCYTIC DEPLETION INVOLVING INTRATHORACIC LYMPH NODES
201.73 HODGKIN'S DISEASE LYMPHOCYTIC DEPLETION INVOLVING INTRA-ABDOMINAL LYMPH NODES
201.74 HODGKIN'S DISEASE LYMPHOCYTIC DEPLETION INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB
201.75 HODGKIN'S DISEASE LYMPHOCYTIC DEPLETION INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
201.76 HODGKIN'S DISEASE LYMPHOCYTIC DEPLETION INVOLVING INTRAPELVIC LYMPH NODES
201.77 HODGKIN'S DISEASE LYMPHOCYTIC DEPLETION INVOLVING SPLEEN
201.78 HODGKIN'S DISEASE LYMPHOCYTIC DEPLETION INVOLVING LYMPH NODES OF MULTIPLE SITES
201.90 HODGKIN'S DISEASE UNSPECIFIED TYPE UNSPECIFIED SITE
201.91 HODGKIN'S DISEASE UNSPECIFIED TYPE INVOLVING LYMPH NODES OF HEAD FACE AND NECK
201.92 HODGKIN'S DISEASE UNSPECIFIED TYPE INVOLVING INTRATHORACIC LYMPH NODES
201.93 HODGKIN'S DISEASE UNSPECIFIED TYPE INVOLVING INTRA-ABDOMINAL LYMPH NODES
201.94 HODGKIN'S DISEASE UNSPECIFIED TYPE INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB
201.95 HODGKIN'S DISEASE UNSPECIFIED TYPE INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
201.96 HODGKIN'S DISEASE UNSPECIFIED TYPE INVOLVING INTRAPELVIC LYMPH NODES
201.97 HODGKIN'S DISEASE UNSPECIFIED TYPE INVOLVING SPLEEN
201.98 HODGKIN'S DISEASE UNSPECIFIED TYPE INVOLVING LYMPH NODES OF MULTIPLE SITES
202.00 NODULAR LYMPHOMA UNSPECIFIED SITE
202.01 NODULAR LYMPHOMA INVOLVING LYMPH NODES OF HEAD FACE AND NECK
202.02 NODULAR LYMPHOMA INVOLVING INTRATHORACIC LYMPH NODES
202.03 NODULAR LYMPHOMA INVOLVING INTRA-ABDOMINAL LYMPH NODES
202.04 NODULAR LYMPHOMA INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB
202.05 NODULAR LYMPHOMA INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
202.06 NODULAR LYMPHOMA INVOLVING INTRAPELVIC LYMPH NODES
202.07 NODULAR LYMPHOMA INVOLVING SPLEEN
202.08 NODULAR LYMPHOMA INVOLVING LYMPH NODES OF MULTIPLE SITES
202.10 MYCOSIS FUNGOIDES UNSPECIFIED SITE
202.11 MYCOSIS FUNGOIDES INVOLVING LYMPH NODES OF HEAD FACE AND NECK
202.12 MYCOSIS FUNGOIDES INVOLVING INTRATHORACIC LYMPH NODES
202.13 MYCOSIS FUNGOIDES INVOLVING INTRA-ABDOMINAL LYMPH NODES
202.14 MYCOSIS FUNGOIDES INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB
202.15 MYCOSIS FUNGOIDES INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
202.16 MYCOSIS FUNGOIDES INVOLVING INTRAPELVIC LYMPH NODES
202.17 MYCOSIS FUNGOIDES INVOLVING SPLEEN
202.18 MYCOSIS FUNGOIDES INVOLVING LYMPH NODES OF MULTIPLE SITES
202.20 SEZARY'S DISEASE UNSPECIFIED SITE
202.21 SEZARY'S DISEASE INVOLVING LYMPH NODES OF HEAD FACE AND NECK
202.22 SEZARY'S DISEASE INVOLVING INTRATHORACIC LYMPH NODES
202.23 SEZARY'S DISEASE INVOLVING INTRA-ABDOMINAL LYMPH NODES
202.24 SEZARY'S DISEASE INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB
202.25 SEZARY'S DISEASE INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
202.26 SEZARY'S DISEASE INVOLVING INTRAPELVIC LYMPH NODES
202.27 SEZARY'S DISEASE INVOLVING SPLEEN
202.28 SEZARY'S DISEASE INVOLVING LYMPH NODES OF MULTIPLE SITES
202.30 MALIGNANT HISTIOCYTOSIS UNSPECIFIED SITE
202.31 MALIGNANT HISTIOCYTOSIS INVOLVING LYMPH NODES OF HEAD FACE AND NECK
202.32 MALIGNANT HISTIOCYTOSIS INVOLVING INTRATHORACIC LYMPH NODES
202.33 MALIGNANT HISTIOCYTOSIS INVOLVING INTRA-ABDOMINAL LYMPH NODES
202.34 MALIGNANT HISTIOCYTOSIS INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB
202.35 MALIGNANT HISTIOCYTOSIS INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
202.36 MALIGNANT HISTIOCYTOSIS INVOLVING INTRAPELVIC LYMPH NODES
202.37 MALIGNANT HISTIOCYTOSIS INVOLVING SPLEEN
202.38 MALIGNANT HISTIOCYTOSIS INVOLVING LYMPH NODES OF MULTIPLE SITES
202.40 LEUKEMIC RETICULOENDOTHELIOSIS UNSPECIFIED SITE
202.41 LEUKEMIC RETICULOENDOTHELIOSIS INVOLVING LYMPH NODES OF HEAD FACE AND NECK
202.42 LEUKEMIC RETICULOENDOTHELIOSIS INVOLVING INTRATHORACIC LYMPH NODES
202.43 LEUKEMIC RETICULOENDOTHELIOSIS INVOLVING INTRA-ABDOMINAL LYMPH NODES
202.44 LEUKEMIC RETICULOENDOTHELIOSIS INVOLVING LYMPH NODES OF AXILLA AND UPPER ARM
202.45 LEUKEMIC RETICULOENDOTHELIOSIS INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
202.46 LEUKEMIC RETICULOENDOTHELIOSIS INVOLVING INTRAPELVIC LYMPH NODES
202.47 LEUKEMIC RETICULOENDOTHELIOSIS INVOLVING SPLEEN
202.48 LEUKEMIC RETICULOENDOTHELIOSIS INVOLVING LYMPH NODES OF MULTIPLE SITES
202.50 LETTERER-SIWE DISEASE UNSPECIFIED SITE
202.51 LETTERER-SIWE DISEASE INVOLVING LYMPH NODES OF HEAD FACE AND NECK
202.52 LETTERER-SIWE DISEASE INVOLVING INTRATHORACIC LYMPH NODES
202.53 LETTERER-SIWE DISEASE INVOLVING INTRA-ABDOMINAL LYMPH NODES
202.54 LETTERER-SIWE DISEASE INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB
202.55 LETTERER-SIWE DISEASE INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
202.56 LETTERER-SIWE DISEASE INVOLVING INTRAPELVIC LYMPH NODES
202.57 LETTERER-SIWE DISEASE INVOLVING SPLEEN
202.58 LETTERER-SIWE DISEASE INVOLVING LYMPH NODES OF MULTIPLE SITES
202.60 MALIGNANT MAST CELL TUMORS UNSPECIFIED SITE
202.61 MALIGNANT MAST CELL TUMORS INVOLVING LYMPH NODES OF HEAD FACE AND NECK
202.62 MALIGNANT MAST CELL TUMORS INVOLVING INTRATHORACIC LYMPH NODES
202.63 MALIGNANT MAST CELL TUMORS INVOLVING INTRA-ABDOMINAL LYMPH NODES
202.64 MALIGNANT MAST CELL TUMORS INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB
202.65 MALIGNANT MAST CELL TUMORS INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
202.66 MALIGNANT MAST CELL TUMORS INVOLVING INTRAPELVIC LYMPH NODES
202.67 MALIGNANT MAST CELL TUMORS INVOLVING SPLEEN
202.68 MALIGNANT MAST CELL TUMORS INVOLVING LYMPH NODES OF MULTIPLE SITES
202.70 PERIPHERAL T CELL LYMPHOMA, UNSPECIFIED SITE, EXTRANODAL AND SOLID ORGAN SITES
202.71 PERIPHERAL T CELL LYMPHOMA, LYMPH NODES OF HEAD, FACE, AND NECK
202.72 PERIPHERAL T CELL LYMPHOMA, INTRATHORACIC LYMPH NODES
202.73 PERIPHERAL T CELL LYMPHOMA, INTRA-ABDOMINAL LYMPH NODES
202.74 PERIPHERAL T CELL LYMPHOMA, LYMPH NODES OF AXILLA AND UPPER LIMB
202.75 PERIPHERAL T CELL LYMPHOMA, LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
202.76 PERIPHERAL T CELL LYMPHOMA, INTRAPELVIC LYMPH NODES
202.77 PERIPHERAL T CELL LYMPHOMA, SPLEEN
202.78 PERIPHERAL T CELL LYMPHOMA, LYMPH NODES OF MULTIPLE SITES
202.80 OTHER MALIGNANT LYMPHOMAS UNSPECIFIED SITE
202.81 OTHER MALIGNANT LYMPHOMAS INVOLVING LYMPH NODES OF HEAD FACE AND NECK
202.82 OTHER MALIGNANT LYMPHOMAS INVOLVING INTRATHORACIC LYMPH NODES
202.83 OTHER MALIGNANT LYMPHOMAS INVOLVING INTRA-ABDOMINAL LYMPH NODES
202.84 OTHER MALIGNANT LYMPHOMAS INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB
202.85 OTHER MALIGNANT LYMPHOMAS INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
202.86 OTHER MALIGNANT LYMPHOMAS INVOLVING INTRAPELVIC LYMPH NODES
202.87 OTHER MALIGNANT LYMPHOMAS INVOLVING SPLEEN
202.88 OTHER MALIGNANT LYMPHOMAS INVOLVING LYMPH NODES OF MULTIPLE SITES
202.90 OTHER AND UNSPECIFIED MALIGNANT NEOPLASMS OF LYMPHOID AND HISTIOCYTIC TISSUE UNSPECIFIED SITE
202.91 OTHER AND UNSPECIFIED MALIGNANT NEOPLASMS OF LYMPHOID AND HISTIOCYTIC TISSUE INVOLVING LYMPH NODES OF HEAD FACE AND NECK
202.92 OTHER AND UNSPECIFIED MALIGNANT NEOPLASMS OF LYMPHOID AND HISTIOCYTIC TISSUE INVOLVING INTRATHORACIC LYMPH NODES
202.93 OTHER AND UNSPECIFIED MALIGNANT NEOPLASMS OF LYMPHOID AND HISTIOCYTIC TISSUE INVOLVING INTRA-ABDOMINAL LYMPH NODES
202.94 OTHER AND UNSPECIFIED MALIGNANT NEOPLASMS OF LYMPHOID AND HISTIOCYTIC TISSUE INVOLVING LYMPH NODES OF AXILLA AND UPPER LIMB
202.95 OTHER AND UNSPECIFIED MALIGNANT NEOPLASMS OF LYMPHOID AND HISTIOCYTIC TISSUE INVOLVING LYMPH NODES OF INGUINAL REGION AND LOWER LIMB
202.96 OTHER AND UNSPECIFIED MALIGNANT NEOPLASMS OF LYMPHOID AND HISTIOCYTIC TISSUE INVOLVING INTRAPELVIC LYMPH NODES
202.97 OTHER AND UNSPECIFIED MALIGNANT NEOPLASMS OF LYMPHOID AND HISTIOCYTIC TISSUE INVOLVING SPLEEN
202.98 OTHER AND UNSPECIFIED MALIGNANT NEOPLASMS OF LYMPHOID AND HISTIOCYTIC TISSUE INVOLVING LYMPH NODES OF MULTIPLE SITES
203.00 MULTIPLE MYELOMA, WITHOUT MENTION OF HAVING ACHIEVED REMISSION
203.01 MULTIPLE MYELOMA IN REMISSION
203.02 MULTIPLE MYELOMA, IN RELAPSE
203.10 PLASMA CELL LEUKEMIA, WITHOUT MENTION OF HAVING ACHIEVED REMISSION
203.11 PLASMA CELL LEUKEMIA IN REMISSION
203.12 PLASMA CELL LEUKEMIA, IN RELAPSE
203.80 OTHER IMMUNOPROLIFERATIVE NEOPLASMS, WITHOUT MENTION OF HAVING ACHIEVED REMISSION
203.81 OTHER IMMUNOPROLIFERATIVE NEOPLASMS IN REMISSION
203.82 OTHER IMMUNOPROLIFERATIVE NEOPLASMS, IN RELAPSE
204.00 ACUTE LYMPHOID LEUKEMIA, WITHOUT MENTION OF HAVING ACHIEVED REMISSION
204.01 LYMPHOID LEUKEMIA ACUTE IN REMISSION
204.02 ACUTE LYMPHOID LEUKEMIA, IN RELAPSE
204.10 CHRONIC LYMPHOID LEUKEMIA, WITHOUT MENTION OF HAVING ACHIEVED REMISSION
204.11 LYMPHOID LEUKEMIA CHRONIC IN REMISSION
204.12 CHRONIC LYMPHOID LEUKEMIA, IN RELAPSE
204.20 SUBACUTE LYMPHOID LEUKEMIA, WITHOUT MENTION OF HAVING ACHIEVED REMISSION
204.21 LYMPHOID LEUKEMIA SUBACUTE IN REMISSION
204.22 SUBACUTE LYMPHOID LEUKEMIA, IN RELAPSE
204.80 OTHER LYMPHOID LEUKEMIA, WITHOUT MENTION OF HAVING ACHIEVED REMISSION
204.81 OTHER LYMPHOID LEUKEMIA IN REMISSION
204.82 OTHER LYMPHOID LEUKEMIA, IN RELAPSE
204.90 UNSPECIFIED LYMPHOID LEUKEMIA, WITHOUT MENTION OF HAVING ACHIEVED REMISSION
204.91 UNSPECIFIED LYMPHOID LEUKEMIA IN REMISSION
204.92 UNSPECIFIED LYMPHOID LEUKEMIA, IN RELAPSE
209.00 MALIGNANT CARCINOID TUMOR OF THE SMALL INTESTINE, UNSPECIFIED PORTION
209.01 MALIGNANT CARCINOID TUMOR OF THE DUODENUM
209.02 MALIGNANT CARCINOID TUMOR OF THE JEJUNUM
209.03 MALIGNANT CARCINOID TUMOR OF THE ILEUM
209.10 MALIGNANT CARCINOID TUMOR OF THE LARGE INTESTINE, UNSPECIFIED PORTION
209.11 MALIGNANT CARCINOID TUMOR OF THE APPENDIX
209.12 MALIGNANT CARCINOID TUMOR OF THE CECUM
209.13 MALIGNANT CARCINOID TUMOR OF THE ASCENDING COLON
209.14 MALIGNANT CARCINOID TUMOR OF THE TRANSVERSE COLON
209.15 MALIGNANT CARCINOID TUMOR OF THE DESCENDING COLON
209.16 MALIGNANT CARCINOID TUMOR OF THE SIGMOID COLON
209.17 MALIGNANT CARCINOID TUMOR OF THE RECTUM
209.20 MALIGNANT CARCINOID TUMOR OF UNKNOWN PRIMARY SITE
209.21 MALIGNANT CARCINOID TUMOR OF THE BRONCHUS AND LUNG
209.22 MALIGNANT CARCINOID TUMOR OF THE THYMUS
209.23 MALIGNANT CARCINOID TUMOR OF THE STOMACH
209.24 MALIGNANT CARCINOID TUMOR OF THE KIDNEY
209.25 MALIGNANT CARCINOID TUMOR OF FOREGUT, NOT OTHERWISE SPECIFIED
209.26 MALIGNANT CARCINOID TUMOR OF MIDGUT, NOT OTHERWISE SPECIFIED
209.27 MALIGNANT CARCINOID TUMOR OF HINDGUT, NOT OTHERWISE SPECIFIED
209.29 MALIGNANT CARCINOID TUMOR OF OTHER SITES
209.30 MALIGNANT POORLY DIFFERENTIATED NEUROENDOCRINE CARCINOMA, ANY SITE
209.31 MERKEL CELL CARCINOMA OF THE FACE
209.32 MERKEL CELL CARCINOMA OF THE SCALP AND NECK
209.33 MERKEL CELL CARCINOMA OF THE UPPER LIMB
209.34 MERKEL CELL CARCINOMA OF THE LOWER LIMB
209.35 MERKEL CELL CARCINOMA OF THE TRUNK
209.36 MERKEL CELL CARCINOMA OF OTHER SITES
209.70 SECONDARY NEUROENDOCRINE TUMOR, UNSPECIFIED SITE
209.71 SECONDARY NEUROENDOCRINE TUMOR OF DISTANT LYMPH NODES
209.72 SECONDARY NEUROENDOCRINE TUMOR OF LIVER
209.73 SECONDARY NEUROENDOCRINE TUMOR OF BONE
209.74 SECONDARY NEUROENDOCRINE TUMOR OF PERITONEUM
209.75 SECONDARY MERKEL CELL CARCINOMA
209.79 SECONDARY NEUROENDOCRINE TUMOR OF OTHER SITES
230.0 CARCINOMA IN SITU OF LIP ORAL CAVITY AND PHARYNX
230.1 CARCINOMA IN SITU OF ESOPHAGUS
230.2 CARCINOMA IN SITU OF STOMACH
230.3 CARCINOMA IN SITU OF COLON
230.4 CARCINOMA IN SITU OF RECTUM
230.5 CARCINOMA IN SITU OF ANAL CANAL
230.6 CARCINOMA IN SITU OF ANUS UNSPECIFIED
230.7 CARCINOMA IN SITU OF OTHER AND UNSPECIFIED PARTS OF INTESTINE
230.8 CARCINOMA IN SITU OF LIVER AND BILIARY SYSTEM
230.9 CARCINOMA IN SITU OF OTHER AND UNSPECIFIED DIGESTIVE ORGANS
231.0 CARCINOMA IN SITU OF LARYNX
231.1 CARCINOMA IN SITU OF TRACHEA
231.2 CARCINOMA IN SITU OF BRONCHUS AND LUNG
231.8 CARCINOMA IN SITU OF OTHER SPECIFIED PARTS OF RESPIRATORY SYSTEM
231.9 CARCINOMA IN SITU OF RESPIRATORY SYSTEM PART UNSPECIFIED
232.0 CARCINOMA IN SITU OF SKIN OF LIP
232.1 CARCINOMA IN SITU OF EYELID INCLUDING CANTHUS
232.2 CARCINOMA IN SITU OF SKIN OF EAR AND EXTERNAL AUDITORY CANAL
232.3 CARCINOMA IN SITU OF SKIN OF OTHER AND UNSPECIFIED PARTS OF FACE
232.4 CARCINOMA IN SITU OF SCALP AND SKIN OF NECK
232.5 CARCINOMA IN SITU OF SKIN OF TRUNK EXCEPT SCROTUM
232.6 CARCINOMA IN SITU OF SKIN OF UPPER LIMB INCLUDING SHOULDER
232.7 CARCINOMA IN SITU OF SKIN OF LOWER LIMB INCLUDING HIP
232.8 CARCINOMA IN SITU OF OTHER SPECIFIED SITES OF SKIN
232.9 CARCINOMA IN SITU OF SKIN SITE UNSPECIFIED
233.0 CARCINOMA IN SITU OF BREAST
233.1 CARCINOMA IN SITU OF CERVIX UTERI
233.2 CARCINOMA IN SITU OF OTHER AND UNSPECIFIED PARTS OF UTERUS
233.30 CARCINOMA IN SITU, UNSPECIFIED FEMALE GENITAL ORGAN
233.31 CARCINOMA IN SITU, VAGINA
233.32 CARCINOMA IN SITU, VULVA
233.39 CARCINOMA IN SITU, OTHER FEMALE GENITAL ORGAN
233.4 CARCINOMA IN SITU OF PROSTATE
233.5 CARCINOMA IN SITU OF PENIS
233.6 CARCINOMA IN SITU OF OTHER AND UNSPECIFIED MALE GENITAL ORGANS
233.7 CARCINOMA IN SITU OF BLADDER
233.9 CARCINOMA IN SITU OF OTHER AND UNSPECIFIED URINARY ORGANS
234.0 CARCINOMA IN SITU OF EYE
234.8 CARCINOMA IN SITU OF OTHER SPECIFIED SITES
234.9 CARCINOMA IN SITU SITE UNSPECIFIED
235.0 NEOPLASM OF UNCERTAIN BEHAVIOR OF MAJOR SALIVARY GLANDS
235.1 NEOPLASM OF UNCERTAIN BEHAVIOR OF LIP ORAL CAVITY AND PHARYNX
235.2 NEOPLASM OF UNCERTAIN BEHAVIOR OF STOMACH INTESTINES AND RECTUM
235.3 NEOPLASM OF UNCERTAIN BEHAVIOR OF LIVER AND BILIARY PASSAGES
235.4 NEOPLASM OF UNCERTAIN BEHAVIOR OF RETROPERITONEUM AND PERITONEUM
235.5 NEOPLASM OF UNCERTAIN BEHAVIOR OF OTHER AND UNSPECIFIED DIGESTIVE ORGANS
235.6 NEOPLASM OF UNCERTAIN BEHAVIOR OF LARYNX
235.7 NEOPLASM OF UNCERTAIN BEHAVIOR OF TRACHEA BRONCHUS AND LUNG
235.8 NEOPLASM OF UNCERTAIN BEHAVIOR OF PLEURA THYMUS AND MEDIASTINUM
235.9 NEOPLASM OF UNCERTAIN BEHAVIOR OF OTHER AND UNSPECIFIED RESPIRATORY ORGANS
236.0 NEOPLASM OF UNCERTAIN BEHAVIOR OF UTERUS
236.1 NEOPLASM OF UNCERTAIN BEHAVIOR OF PLACENTA
236.2 NEOPLASM OF UNCERTAIN BEHAVIOR OF OVARY
236.3 NEOPLASM OF UNCERTAIN BEHAVIOR OF OTHER AND UNSPECIFIED FEMALE GENITAL ORGANS
236.4 NEOPLASM OF UNCERTAIN BEHAVIOR OF TESTIS
236.5 NEOPLASM OF UNCERTAIN BEHAVIOR OF PROSTATE
236.6 NEOPLASM OF UNCERTAIN BEHAVIOR OF OTHER AND UNSPECIFIED MALE GENITAL ORGANS
236.7 NEOPLASM OF UNCERTAIN BEHAVIOR OF BLADDER
236.90 NEOPLASM OF UNCERTAIN BEHAVIOR OF URINARY ORGAN UNSPECIFIED
236.91 NEOPLASM OF UNCERTAIN BEHAVIOR OF KIDNEY AND URETER
236.99 NEOPLASM OF UNCERTAIN BEHAVIOR OF OTHER AND UNSPECIFIED URINARY ORGANS
237.0 NEOPLASM OF UNCERTAIN BEHAVIOR OF PITUITARY GLAND AND CRANIOPHARYNGEAL DUCT
237.1 NEOPLASM OF UNCERTAIN BEHAVIOR OF PINEAL GLAND
237.2 NEOPLASM OF UNCERTAIN BEHAVIOR OF ADRENAL GLAND
237.3 NEOPLASM OF UNCERTAIN BEHAVIOR OF PARAGANGLIA
237.4 NEOPLASM OF UNCERTAIN BEHAVIOR OF OTHER AND UNSPECIFIED ENDOCRINE GLANDS
237.5 NEOPLASM OF UNCERTAIN BEHAVIOR OF BRAIN AND SPINAL CORD
237.6 NEOPLASM OF UNCERTAIN BEHAVIOR OF MENINGES
237.70 NEUROFIBROMATOSIS UNSPECIFIED
237.71 NEUROFIBROMATOSIS TYPE 1 VON RECKLINGHAUSEN'S DISEASE
237.72 NEUROFIBROMATOSIS TYPE 2 ACOUSTIC NEUROFIBROMATOSIS
237.73 SCHWANNOMATOSIS
237.79 OTHER NEUROFIBROMATOSIS
237.9 NEOPLASM OF UNCERTAIN BEHAVIOR OF OTHER AND UNSPECIFIED PARTS OF NERVOUS SYSTEM
238.0 NEOPLASM OF UNCERTAIN BEHAVIOR OF BONE AND ARTICULAR CARTILAGE
238.1 NEOPLASM OF UNCERTAIN BEHAVIOR OF CONNECTIVE AND OTHER SOFT TISSUE
238.2 NEOPLASM OF UNCERTAIN BEHAVIOR OF SKIN
238.3 NEOPLASM OF UNCERTAIN BEHAVIOR OF BREAST
238.4 POLYCYTHEMIA VERA
238.5 NEOPLASM OF UNCERTAIN BEHAVIOR OF HISTIOCYTIC AND MAST CELLS
238.6 NEOPLASM OF UNCERTAIN BEHAVIOR OF PLASMA CELLS
238.8 NEOPLASM OF UNCERTAIN BEHAVIOR OF OTHER SPECIFIED SITES
238.9 NEOPLASM OF UNCERTAIN BEHAVIOR SITE UNSPECIFIED
239.0 NEOPLASM OF UNSPECIFIED NATURE OF DIGESTIVE SYSTEM
239.1 NEOPLASM OF UNSPECIFIED NATURE OF RESPIRATORY SYSTEM
239.2 NEOPLASM OF UNSPECIFIED NATURE OF BONE SOFT TISSUE AND SKIN
239.3 NEOPLASM OF UNSPECIFIED NATURE OF BREAST
239.4 NEOPLASM OF UNSPECIFIED NATURE OF BLADDER
239.5 NEOPLASM OF UNSPECIFIED NATURE OF OTHER GENITOURINARY ORGANS
239.6 NEOPLASM OF UNSPECIFIED NATURE OF BRAIN
239.7 NEOPLASM OF UNSPECIFIED NATURE OF ENDOCRINE GLANDS AND OTHER PARTS OF NERVOUS SYSTEM
239.81 NEOPLASMS OF UNSPECIFIED NATURE, RETINA AND CHOROID
239.89 NEOPLASMS OF UNSPECIFIED NATURE, OTHER SPECIFIED SITES
239.9 NEOPLASM OF UNSPECIFIED NATURE SITE UNSPECIFIED
285.3 ANTINEOPLASTIC CHEMOTHERAPY INDUCED ANEMIA
The following list applies to J0882, J0886, and J0890 only. A dual diagnosis is required for all claims billing J0882, J0886, or J0890.
Dual Diagnosis Rule:
* 285.21 and 585.6 must be billed together.
285.21* ANEMIA IN CHRONIC KIDNEY DISEASE
585.6* END STAGE RENAL DISEASE
* Diagnosis codes marked with an * require a dual diagnosis.
Documentation Requirements
• This is not an all- inclusive list.
• Providers are responsible for ensuring that all requirements outlined in the LCD are documented clearly and support the medical necessity for ESA therapy.
o The medical record must reflect that the patient meets all requirements for coverage outlined in this LCD.
o The medical record must contain a history and physical that includes the following information:
Most recent blood pressure.
Evidence that patients with elevated blood pressure are being adequately controlled.
Weight in Kg.
Date and results of Hct and Hgb level prior to the initiation of ESA therapy.
Assessment that rules out other causative factors of anemia.
Or
If causative factors are present, that:
• They have been managed.
And
• It is still necessary to initiate ESA therapy.
o The dosage and route of administration must be documented.
• The medical record must support that Hgb and Hct levels are documented at the frequencies outlined for each indication and that doses are being titrated or withheld/re-initiated according to the indications, limitations and utilization guidelines outlined in the LCD.
• In addition to the above, the following are documentation requirements that are specific to certain indications.
• Prior to and during ESA therapy for CKD patients, the patient’s iron stores, including transferrin saturation and serum ferritin, should be evaluated.
o Transferrin saturation should be at least 20%, and ferritin should be at least 100 ng/mL
• For HIV-infected patients with anemia related to Zidovudine treatment, the medical record must contain the endogenous erythropoietin level (prior to transfusion).
o If levels are > 500mUnits.mL, patients are unlikely to respond to therapy with epoetin alfa.
o The patient’s current dose of Zidovudine should be documented in the medical record.
• For patients with anemia related to anemia of Hepatitis C, the medical record must support that the patient is being treated with the combination of ribavirin and interferon alfa or ribavarin and peginterferon alfa.
• For patients with RA, the medical record must show that the patient has been diagnosed with RA using the American College of Rheumatology criteria.
o Patients are usually on an anti-metabolite (e.g., Methotrexate), which causes the anemia.
o If the anemia is caused by factors other than an anti-metabolite, the medical record should justify the initiation of ESA therapy and that the causative factor cannot be managed without ESA therapy.
• For patients with MDS, the medical record must contain a bone marrow biopsy or aspiration report confirming a diagnosis of MDS.
• For cancer patients with anemia related to chemotherapy, the date of the last chemotherapy treatment must be documented.
o A course of chemotherapy includes the 8 weeks following the last dose of chemotherapy for that course of treatment.
o After 8 weeks, ESA treatment is not medically necessary.
• For cancer patients with anemia related to myelosuppressive chemotherapy, the medical record should support that the provider is enrolled in the ESA APPRISE Oncology Program and meets the program requirements.
• For all patients with CKD receiving ESAs:
o When initiating or adjusting therapy, monitor hemoglobin levels at least weekly until stable, then monitor at least monthly.
o When adjusting therapy consider hemoglobin rate of rise, rate of decline, ESA responsiveness and hemoglobin variability.
o A single hemoglobin excursion may not require a dosing change.
o Do not increase the dose more frequently than once every 4 weeks.
Decrease in dose can occur more frequently.
Avoid frequent dose adjustments.
If the hemoglobin rises rapidly (e.g., more than 1 g/dL in any 2-week period), reduce the dose of ESA by 25% or more as needed to reduce rapid responses.
For patients who do not respond adequately, if the hemoglobin has not increased by more than 1 g/dL after 4 weeks of therapy, increase the dose by 25%.
For patients who do not respond adequately over a 12 week escalation period, increasing the ESA dose further is unlikely to improve response and may increase risks.
Use the lowest dose that will maintain a hemoglobin level sufficient to reduce the need for RBC transfusions.
Evaluate other causes of anemia Discontinue the ESA if responsiveness does not improve.
o To initiate ESA therapy for other covered indications in this LCD, except for preoperative use and for anemia in cancer patients on chemotherapy, the patient must have a documented anemia as evidenced by symptoms and a Hct of < 33% or a Hgb < 11 g/dL, unless there is medical documentation showing the need for ESA therapy despite a Hct of >32.9 or a Hgb >10.9 g/dL.
It may be medically necessary for a patient to initiate ESA therapy when the patient exhibits signs and symptoms such as extreme weakness and fatigue, cold intolerance, tachycardia, pulmonary distress, hypotension, angina, congestive heart failure, etc., which is caused by the anemic condition and Hct is >32.9 % and the Hgb is >10.9 g/dL.
o For anemia in cancer patients on chemotherapy, please refer to the National Coverage Decision language found under the “limitations” section of this LCD for coverage requirements.
In order to prescribe and/or dispense ESAs to patients with cancer and anemia due to myelosuppressive chemotherapy, prescribers and hospitals must enroll in and comply with the ESA APPRISE Oncology Program requirements.
DOSAGE AND ADMINISTRATION REQUIREMENTS:
• Epoetin alfa (Procrit and Epogen)
• Treatment of anemia for CKD patients on dialysis:
o Initiate Epoetin alfa treatment when the hemoglobin level is less than 10 g/dL.
o If the hemoglobin level approaches or exceeds 11 g/dL, reduce or interrupt the dose of epoetin alfa.
o The recommended starting dose for adult patients is 50 to 100 Units/kg 3 times weekly intravenously or subcutaneously.
o The intravenous route is recommended for patients on dialysis.
• Treatment of anemia for CKD patients not on dialysis:
o Consider initiating epoetin alfa treatment only when the hemoglobin level is less than 10 g/dL and the following considerations apply:
The rate of hemoglobin decline indicates the likelihood of requiring a RBC transfusion and reducing the risk of alloimmunization and/or other RBC transfusion-related risks is a goal.
If the hemoglobin level exceeds 10 g/dL, reduce or interrupt the dose of epoetin alfa, and use the lowest dose of epoetin alfa sufficient to reduce the need for RBC transfusions.
The recommended starting dose for adult patients is 50-100 Units/kg 3 times weekly intravenously or subcutaneously.
• Treatment of anemia in Zidovudine-treated HIV-infected patients:
o Starting Dose:
The recommended starting dose in adults is 100 Units/kg as an intravenous or subcutaneous injection 3 times per week.
o Dose Adjustment:
If hemoglobin does not increase after 8 weeks of therapy, increase epoetin alfa dose by approximately 50-100 Units/kg at 4 to 8 week intervals until hemoglobin reaches a level needed to avoid RBC transfusions or 300 Units/kg.
Withhold the epoetin alfa if hemoglobin exceeds 12 g/dL. Resume therapy at a dose 25% below the previous dose when hemoglobin declines to less than 11 g/dL.
Discontinue epoetin alfa if an increase in hemoglobin is not achieved at a dose of 300 Units/kg for 8 weeks.
• Reduction of allogenic blood transfusions in surgery patients
o Prior to initiating epoetin alfa therapy a hemoglobin level should be obtained to establish that it is greater than 10 and less than or equal 13 g/dL.
o The recommended epoetin alfa regimens are:
300 Units/kg per day subcutaneously for 14 days total: administered daily for 10 days before surgery, on the day of surgery and for 4 days after surgery.
600 Units/kg subcutaneously in 4 doses administered 21, 14 and 7 days before surgery and on the day of surgery.
• Treatment of anemia in cancer patients on chemotherapy:
o For therapy initiation, dose adjustments and maintenance doses see the National Coverage Decision language found under the limitations section of this LCD.
• Anemia associated with myelodysplastic syndrome (MDS) and anemia associated with Rheumatoid Arthritis
o The recommended starting dose of epoetin alfa is 150 units/kg subcutaneously three times weekly or 40,000 units subcutaneously weekly.
o Dose modification three times weekly dosing:
Reduce dose by 25% when the hemoglobin approaches 12 g/dL or when the hemoglobin increases > 1 g/dL in any two week period.
Withhold the dose when the hemoglobin exceeds 12 g/dl, until the hemoglobin falls below 11 g/dL and restart the dose at 25% below the previous dose.
Increase the dose to 300 units/kg three times weekly if the response is not satisfactory (no reduction in transfusion requirements or rise in hemoglobin) after 8 weeks to achieve and maintain the lowest hemoglobin level sufficient to avoid the need for red blood cell transfusion and not to exceed 12 g/dL.
o Dose modification weekly dosing:
Reduce dose by 25% when the hemoglobin approaches 12 g/dL or increases >1 g/dL in any 2 weeks
Withhold dose if the hemoglobin exceeds 12 g/dL, until the hemoglobin falls below 11 g/dL, and restart the dose at 25% below the previous dose.
The dose may be increased to 60,000 units subcutaneously weekly if the response is not satisfactory (no reduction in transfusion requirements or rise in hemoglobin) after 8 weeks to achieve and maintain the lowest hemoglobin level sufficient to avoid the need for red blood cell transfusion and not to exceed 12 g/dL.
• The off-label maintenance dosing schedule for MDS patients:
o 120,000 units subcutaneously once every three weeks to maintain the target hemoglobin.
o This dosing schedule must not be used as an initial dosing schedule.
o The hemoglobin should not exceed 12 g/dL.
o The patient should already be receiving epoetin alfa and responding to the therapy as evidenced by Hgb rising at least 2 g/dL, not exceeding 12 g/dL.
• Treatment of chronic anemia associated with the management of Hepatitis C:
o The usual dose for this indication is 40,000 units subcutaneously once weekly.
Darbepoetin alfa (Aranesp)
• Treatment of chronic kidney disease (CKD):
• Patients on dialysis:
o Initiate Aranesp treatment when the hemoglobin level is less than 10 g/dL
o If the hemoglobin level approaches or exceeds 11 g/dL, reduce or interrupt the dose of Aranesp.
o The recommended starting dose is 0.45 mcg/kg intravenously or subcutaneously as a weekly injection or 0.75 mcg/kg once every 2 weeks as appropriate. The intravenous route is recommended for patients on dialysis.
• Patients not on dialysis:
o Consider initiating Aranesp treatment only when the hemoglobin level is less than 10 g/dL and the following considerations apply:
The rate of hemoglobin decline indicates the likelihood of reporting RBC transfusion and,
Reducing the risk of alloimmunization and/or other RBC transfusion-related risk is a goal.
o If the hemoglobin level exceeds 10 g/dL, reduce or interrupt the dose of Aranesp, and use the lowest dose of Aranesp sufficient to reduce the need for RBC transfusion.
o The recommended starting dose is 0.45 mcg /kg body weight intravenously or subcutaneously given once at four weeks intervals as appropriate.
o For conversion from Epoetin alfa to Aranesp for CKD patients on or off dialysis, refer to the Aranesp FDA approved product label for doses and tables.
• Treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy:
o For therapy initiation, dose adjustments and maintenance doses see the National Coverage Decision language found under the limitations section of this LCD.
• Anemia associated with myelodysplastic syndrome (MDS):
• The recommended starting dose for MDS patients is similar to those for FDA approved indications found in the package insert and outlined in this LCD for darbepoetin alfa.
• Refer to the package insert for additional dose adjustment or maintenance dose schedules.
• Doses should be reduced to maintain Hgb levels ≤12 g/dL.
• Hemoglobin levels that increase to or approach 12 g/dL should be reduced by approximately 25%.
• If hemoglobin levels continue to increase above 12 g/dL, doses should be temporarily withheld until the hemoglobin begins to decrease, at which time the therapy can be reinitiated at a dose approximately 25% below the previous dose.
• A rise in hemoglobin >1 g/dL in any two week period requires the dose to be reduced by 25%.
Peginesatide (OMONTYS®)
Treatment of anemia for CKD patients on dialysis:
• Initiate Peginesatide treatment when the hemoglobin level is less than 10 g/dL.
• The recommended starting dose for the treatment of anemia in patients who are not currently treated with an ESA is 0.04 mg/kg body weight administered as a single intravenous or subcutaneous injection once monthly
• If the hemoglobin level approaches or exceeds 11 g/dL, reduce or interrupt the dose of peginesatide. After a dose has been withheld and once the hemoglobin begins to decrease, peginesatide may be restarted at a dose approximately 25% below the previously administered dose.
• For conversion from Epoetin Alfa and Darbepoetin Alfa to Peginesatide in patients with CKD on dialysis, refer to the Peginesatide FDA approved product label for doses and tables.
Treatment Logic:
• Epoetin alfa (Epogen® and Procrit®) and Darbepoetin alfa (Aranesp®) are erythropoetin analogs produced in the Chinese hamster ovary, that are 165 amino acid gylcoproteins manufactured by recombinant DNA technology.
o Epoetin alfa has the same amino acid sequence of naturally occurring erythropoietin.
o Darbepoetin has 2 additional 5 N-linked oligosaccharide chains, which slows its clearance, making its half- life 2-3 times longer than that of epoetin alfa, thus allowing less frequent subcutaneous or intravenous injections.
• Erythropoietin is a specialized cytokein that is produced by the kidneys and stimulates the proliferation of red blood cells in the bone marrow.
o Erythropoietin is released into the blood stream in response to hypoxia.
o In response to the hypoxia, the erythropoietin interacts with the progenitor cells to increase the production of red blood cells.
Sources of Information and Basis for Decision
ACCC drug database (2007) Darbepoetin alfa (Systemic).
ACCC drug database (2007) Epoetin alfa (systemic)
Amgen (2008) Prescribing information, Darbepoetin alfa and Epogen. Located at www.amgen .com
Amgen (2011) Prescribing information, Darbepoetin alfa (Aranesp®) and Epogen®.
Aranesp Effective in Low-Intermediate Risk MDS, University of Florida Shands Cancer Center. www.ufscc.ufl.edu/cancernews on 5/18/2005.
Centocor Ortho Biotech Products, L.P. (2011). Prescribing information, Procrit®.
Dear Health Care Professional Letter (8/7/2008)located at www.amgen.com , www.fda.gov and www.orthobiotech.com
FCSO LCD 29168, Erythropoiesis Stimulating Agents, 01/01/2013. The official local coverage determination (LCD) is the version on the Medicare coverage database at www.cms.gov/medicare-coverage-database/.
Food and Drug Administration. FDA Alert 11/16/2007, 2/16/2007 and 3/9/2007. Eryhtropoiesis Stimulating Agents (ESA). www.fda.gov/cder/drug/infopage/RHE/default.htm
Food and Drug Administration. (2012). OMONTYS® (peginesatide) prescribing information. Retrieved from http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=202799&DrugName=OMONTYS&ActiveIngred=PEGINESATIDE%20ACETATE&SponsorApplicant=AFFYMAX&ProductMktStatus=1&goto=Search.Label_ApprovalHistory
Gotlib, J. (2005). Myelodysplatic Syndrome (MDS): ASH 2005 Update. Retrieved from http://www.anco-online.org/gotlibppt.pdf
Ortho Biotech Products, LP (2008). Prescribing information Procrit. Located at www.orthobiotech.com
AMA CPT / ADA CDT Copyright Statement
CPT codes, descriptions and other data only are copyright 2011 American Medical Association (or such other date of publication of CPT). All Rights Reserved. Applicable FARS/DFARS Clauses Apply. Current Dental Terminology, (CDT) (including procedure codes, nomenclature, descriptors and other data contained therein) is copyright by the American Dental Association. © 2002, 2004 American Dental Association. All rights reserved. Applicable FARS/DFARS apply.
CMS LCD L29168 ERYTHROPOIESIS STIMULATING AGENTS